Background	O
Infection	O
with	O
Entamoeba	O
histolytica	O
and	O
associated	O
complications	O
are	O
relatively	O
rare	O
in	O
developed	O
countries	O
.	O

The	O
overall	O
low	O
prevalence	B-EPI
in	O
the	O
Western	O
world	O
as	O
well	O
as	O
the	O
possibly	O
prolonged	O
latency	O
period	O
between	O
infection	B-DIS
with	O
the	O
causing	O
pathogen	O
and	O
onset	O
of	O
clinical	O
symptoms	O
may	O
delay	O
diagnosis	O
of	O
and	O
adequate	O
treatment	O
for	O
amoebiasis	B-DIS
.	O

Amoebic	B-DIS
liver	I-DIS
abscess	I-DIS
ALA	I-DIS
is	O
the	O
most	O
common	O
extraintestinal	B-DIS
manifestation	I-DIS
of	O
invasive	O
amoebiasis	B-DIS
.	O

Pregnancy	O
has	O
been	O
described	O
as	O
a	O
risk	O
factor	O
for	O
development	O
of	O
invasive	O
amoebiasis	B-DIS
and	O
management	O
of	O
these	O
patients	O
is	O
especially	O
complex	O
.	O

Case	O
presentation	O
A	O
30	O
-	O
year	O
-	O
old	O
Caucasian	O
woman	O
in	O
early	O
pregnancy	O
presented	O
to	O
our	B-DIS
emergency	I-DIS
department	O
with	O
abdominal	O
pain	O
alongside	O
elevated	O
inflammatory	O
markers	O
and	O
liver	O
function	O
tests	O
.	O

Travel	O
history	O
revealed	O
multiple	O
journeys	O
to	O
tropic	O
and	O
subtropic	O
regions	O
during	O
the	O
past	O
decade	O
and	O
a	O
prolonged	O
episode	O
of	O
intermittently	O
bloody	O
diarrhea	B-DIS
during	O
a	O
five	O
month	O
stay	O
in	O
Indonesia	B-LOC
seven	O
years	O
prior	O
to	O
admission	O
.	O

Sonographic	O
and	O
magnetic	O
resonance	O
imaging	O
revealed	O
a	O
5	O
×	O
4	O
cm	O
hepatic	O
abscess	O
.	O

After	O
ultrasound	O
-	O
guided	O
transcutaneous	O
liver	O
drainage	B-DIS
both	O
abscess	O
fluids	O
and	O
blood	O
cultures	O
showed	O
neither	O
bacterial	O
growth	O
nor	O
microscopic	O
signs	B-DIS
of	I-DIS
parasitic	O
disease	O
.	O

Serological	O
testing	O
confirmed	O
an	O
infection	B-DIS
with	O
Entamoeba	O
histolytica	O
which	O
was	O
treated	O
with	O
metronidazole	O
followed	O
by	O
eradication	O
therapy	O
with	O
paromomycin	O
.	O

Subsequent	O
clinical	O
laboratory	O
and	O
imaging	O
follow	O
-	O
up	O
exams	O
showed	O
regression	O
of	O
the	O
ALA	O
.	O

In	O
addition	O
the	O
pregnancy	O
completed	O
without	O
complications	O
and	O
a	O
healthy	O
baby	O
boy	O
was	O
born	O
7	O
months	O
after	O
termination	O
of	O
treatment	O
.	O

Conclusions	O
This	O
case	O
of	O
invasive	O
amoebiasis	B-DIS
in	O
early	O
pregnancy	O
outside	O
of	O
endemic	O
regions	O
and	O
several	O
years	O
after	O
exposure	O
demonstrates	O
the	O
importance	O
of	O
broad	O
differential	O
diagnostics	O
in	O
the	O
context	O
of	O
liver	B-DIS
abscesses	I-DIS
.	O

The	O
complex	O
interdisciplinary	O
decisions	O
regarding	O
the	O
choice	O
of	O
imaging	O
techniques	O
as	O
well	O
as	O
interventional	O
and	O
antibiotic	O
therapy	O
in	O
the	O
context	O
of	O
pregnancy	O
are	O
discussed	O
.	O

Furthermore	O
we	O
present	O
possible	O
explanations	O
for	O
pregnancy	O
as	O
a	O
risk	O
factor	O
for	O
an	O
invasive	O
course	O
of	O
amoebiasis	B-DIS
.	O

Wilson	B-DIS
's	I-DIS
disease	I-DIS
or	O
hepatolenticular	B-DIS
degeneration	I-DIS
Abstract	O
.	O

Wilson	B-DIS
's	I-DIS
disease	I-DIS
or	O
hepatolenticular	B-DIS
degeneration	I-DIS
is	O
a	O
rare	O
inherited	O
disorder	O
of	O
copper	O
metabolism	O
.	O

The	O
most	O
common	O
clinical	O
presentations	O
are	O
liver	B-DIS
disease	I-DIS
and	O
/	O
or	O
neuro	O
-	O
psychiatric	O
manifestations	O
.	O

Pathophysiologically	O
Wilson	B-DIS
's	I-DIS
disease	I-DIS
is	O
caused	O
by	O
mutations	O
in	O
the	O
ATP7B	O
gene	O
which	O
lead	O
to	O
defective	O
biliary	O
excretion	O
of	O
copper	O
and	O
subsequent	O
accumulation	O
of	O
copper	O
in	O
the	O
liver	O
and	O
in	O
other	O
organs	O
.	O

Its	O
prevalence	B-EPI
is	O
approximately	O
130000	O
however	O
its	O
penetrance	O
clinical	O
presentation	O
and	O
disease	O
severity	O
vary	O
widely	O
ranging	O
from	O
asymptomatic	O
elevation	O
of	O
liver	O
enzymes	O
to	O
cirrhosis	B-DIS
or	O
acute	B-DIS
liver	I-DIS
failure	I-DIS
with	O
or	O
without	O
neuro	B-DIS
-	I-DIS
psychiatric	O
symptoms	O
.	O

For	O
this	O
reason	O
Wilson	B-DIS
's	I-DIS
disease	I-DIS
should	O
be	O
suspected	O
and	O
ruled	O
out	O
in	O
cases	O
of	O
indeterminate	O
liver	B-DIS
disease	I-DIS
or	O
neuropsychiatric	B-DIS
disturbances	I-DIS
.	O

The	O
diagnostic	O
algorithms	O
are	O
complex	O
and	O
involve	O
clinical	O
tests	O
ophthalmologic	O
examination	O
Kayser	O
-	O
Fleischer	O
rings	O
in	O
split	O
-	O
lamp	O
examination	O
blood	O
and	O
urine	O
tests	O
genetic	O
testing	O
imaging	O
and	O
histology	O
.	O

In	O
compensated	O
liver	B-DIS
disease	I-DIS
treatment	O
of	O
Wilson	B-DIS
's	I-DIS
disease	I-DIS
by	O
copper	O
depletion	O
chelators	O
zinc	O
is	O
usually	O
effective	O
.	O

In	O
case	O
of	O
liver	B-DIS
failure	I-DIS
liver	I-DIS
transplantation	O
may	O
be	O
needed	O
which	O
corrects	O
the	O
underlying	O
error	O
of	O
copper	O
metabolism	O
.	O

New	O
drugs	O
with	O
improved	O
efficacy	O
and	O
tolerability	O
are	O
in	O
clinical	O
development	O
.	O

Oculomotor	B-DIS
abnormalities	I-DIS
are	O
common	O
in	O
the	O
spinocerebellar	B-DIS
ataxias	I-DIS
SCAs	I-DIS
.	O

In	O
studies	O
of	O
SCAs	B-DIS
123	I-DIS
and	O
6	O
eye	O
movement	B-DIS
abnormalities	I-DIS
correlate	O
with	O
disease	O
severity	O
.	O

Oculomotor	B-DIS
abnormalities	I-DIS
may	O
be	O
the	O
sole	O
motor	O
manifestation	O
of	O
early	O
and/or	O
premanifest	B-DIS
disease	I-DIS
;	O
however	O
not	O
all	O
ataxia	B-DIS
rating	O
scales	O
include	O
oculomotor	O
assessment	O
.	O

We	O
sought	O
to	O
identify	O
the	O
prevalence	B-EPI
and	O
characteristics	O
of	O
oculomotor	B-DIS
abnormalities	I-DIS
at	O
first	O
presentation	O
in	O
a	O
large	O
SCA	B-DIS
cohort	O
including	O
those	O
in	O
earlier	O
stages	O
of	O
disease	O
.	O

We	O
performed	O
a	O
retrospective	O
assessment	O
of	O
initial	O
clinical	O
examinations	O
of	O
SCA	B-DIS
patients	O
followed	O
in	O
the	O
Massachusetts	O
General	O
Hospital	O
Ataxia	B-DIS
Unit	O
and	O
assessed	O
with	O
the	O
Brief	O
Ataxia	B-DIS
Rating	O
Scale	O
BARS	O
.	O

One	O
hundred	O
thirty	O
-	B-DIS
four	O
SCA	O
patients	O
were	O
assessed	O
17	O
SCA113	O
SCA255	O
SCA32	O
SCA522	O
SCA611	O
SCA79	O
SCA8	O
and	O
5	O
SCA17	O
mainly	O
in	O
the	O
early	O
stages	O
of	O
disease	O
67.2	B-STAT
%	I-STAT
stage	O
0	O
-	O
1	O
.	O

Oculomotor	B-DIS
abnormalities	I-DIS
were	O
present	O
on	O
initial	O
assessment	O
in	O
94.8	B-STAT
%	I-STAT
including	O
7/9	B-STAT
stage	O
0	O
and	O
77/81	B-STAT
stage	O
1	O
patients	O
.	O

Stage	O
0/1	B-STAT
patients	O
had	O
frequent	O
saccadic	O
intrusions	O
nystagmus	B-DIS
and	O
hypo	O
/	O
hypermetric	O
saccades	O
.	O

Saccadic	O
slowing	O
was	O
present	O
even	O
in	O
early	O
stage	O
SCA7	O
and	O
SCA2	O
eventually	O
leading	O
to	O
ophthalmoplegia	B-DIS
.	O

The	O
burden	O
of	O
oculomotor	B-DIS
abnormalities	I-DIS
correlated	O
with	O
disease	O
stage	O
duration	O
and	O
severity	O
remaining	O
highly	O
significant	O
even	O
when	O
controlling	O
for	O
age	O
.	O

The	O
ubiquitous	O
presence	O
of	O
oculomotor	B-DIS
abnormalities	I-DIS
in	O
the	O
SCAs	O
particularly	O
early	O
in	O
the	O
course	O
underscores	O
the	O
importance	O
of	O
oculomotor	O
assessment	O
in	O
ataxia	B-DIS
rating	O
scales	O
such	O
as	O
BARS	O
.	O

These	O
findings	O
highlight	O
the	O
potential	O
for	O
quantitative	O
physiological	O
oculomotor	O
measures	O
as	O
clinical	O
biomarkers	O
in	O
natural	O
history	O
studies	O
and	O
clinical	O
trials	O
.	O

Background	O
Vitamin	O
C	O
deficiency	O
is	O
common	O
in	O
chronic	B-DIS
kidney	I-DIS
disease	I-DIS
CKD	I-DIS
due	O
to	O
losses	O
through	O
dialysis	O
and	O
dietary	O
intake	O
below	O
requirement	O
.	O

We	O
investigated	O
prevalence	B-EPI
of	O
vitamin	O
C	O
deficiency	O
and	O
impact	O
of	O
vitamin	O
C	O
treatment	O
in	O
deficient	O
/	O
insufficient	O
patients	O
.	O

Methods	O
A	O
prospective	O
cohort	O
study	O
in	O
patients	O
aged	O
1	B-STAT
-	I-STAT
18	I-STAT
years	O
with	O
CKD	O
stages	O
4	O
and	O
5D	O
collected	O
demographic	O
data	O
including	O
underlying	O
disease	O
treatment	O
and	O
anthropometric	O
assessment	O
.	O

Vitamin	O
C	O
intake	O
was	O
assessed	O
using	O
24	O
-	O
h	O
dietary	O
recall	O
.	O

Hemoglobin	O
iron	O
status	O
serum	O
vitamin	O
C	O
and	O
serum	O
oxalate	O
were	O
measured	O
at	O
baseline	O
and	O
after	O
treatment	O
.	O

Vitamin	O
C	O
250	O
mg	O
/	O
day	O
was	O
given	O
orally	O
for	O
3	O
months	O
to	O
deficient	O
/	O
insufficient	O
patients	O
.	O

Results	O
Nineteen	O
patients	O
mean	O
age	O
12.00	O
±	O
4.1	O
years	O
showed	O
prevalence	B-EPI
of	O
10.6	B-STAT
%	I-STAT
vitamin	O
C	O
insufficiency	O
and	O
78.9	B-STAT
%	I-STAT
deficiency	O
.	O

There	O
were	O
no	O
associations	O
between	O
vitamin	O
C	O
level	O
and	O
daily	O
vitamin	O
C	O
intake	O
p	O
=	O
0.64	O
or	O
nutritional	O
status	O
p	O
=	O
0.87	O
.	O

Median	O
serum	O
vitamin	O
C	O
was	O
1.51	O
0.30	O
-	O
1.90	O
mg	O
/	O
L	O
.	O

In	O
16	O
patients	O
receiving	O
treatment	O
median	O
serum	O
vitamin	O
C	O
increased	O
from	O
1.30	O
0.23	O
-	O
1.78	O
to	O
3.22	O
1.77	O
-	O
5.96	O
mg	O
/	O
L	O
p	O
=	O
0.008	O
without	O
increasing	O
serum	O
oxalate	O
79.92	O
56.6	O
-	O
106.84	O
vs.	O
80.47	O
56.88	O
-	O
102.95	O
μmol	O
/	O
L	O
p	O
=	O
0.82	O
.	O

However	O
62.5	B-STAT
%	I-STAT
failed	O
to	O
achieve	O
normal	O
vitamin	O
C	O
levels	O
.	O

Ordinal	O
regression	O
analysis	O
revealed	O
patients	O
with	O
non	B-DIS
-	I-DIS
oligoanuric	O
CKD	O
were	O
less	O
likely	O
to	O
achieve	O
normal	O
vitamin	O
C	O
levels	O
β	O
=	O
-	O
3.41	O
p	O
=	O
0.03	O
.	O

Conclusion	O
We	O
describe	O
high	O
prevalence	B-EPI
of	O
vitamin	O
C	O
insufficiency	O
/	O
deficiency	O
among	B-DIS
pediatric	O
CKD	O
patients	O
.	O

Vitamin	O
C	O
levels	O
could	O
not	O
be	O
solely	O
predicted	O
by	O
nutritional	O
status	O
or	O
daily	O
intake	O
.	O

The	O
treatment	O
regimen	O
raised	O
serum	O
vitamin	O
C	O
without	O
increasing	O
serum	O
oxalate	O
;	O
however	O
it	O
was	O
largely	O
insufficient	O
to	O
normalize	O
levels	O
particularly	O
in	O
non	B-DIS
-	I-DIS
oligoanuric	O
CKD	O
.	O

Graphical	O
abstract	O
.	O

The	O
human	B-DIS
T	I-DIS
cell	I-DIS
lymphotropic	I-DIS
virus	I-DIS
type	I-DIS
1	I-DIS
HTLV-1	I-DIS
is	O
the	O
first	O
human	O
retrovirus	O
discovered	O
.	O

Since	O
then	O
it	O
has	O
spread	O
worldwide	O
and	O
is	O
mainly	O
associated	O
with	O
adult	O
T	B-DIS
cell	I-DIS
leukemia	I-DIS
/	I-DIS
lymphoma	O
ATLL	B-DIS
and	I-DIS
HTLV1	O
-	O
associated	O
myelopathy	O
HAM	O
.	O

Its	O
relationship	O
however	O
with	O
other	O
types	O
of	O
cancer	B-DIS
is	O
controversial	O
.	O

We	O
describe	O
the	O
case	O
of	O
a	O
patient	O
presenting	O
with	O
small	O
cells	O
lung	B-DIS
epidermoid	I-DIS
carcinoma	I-DIS
who	O
had	O
recently	O
developed	O
HAM	O
and	O
a	O
review	O
of	O
the	O
literature	O
related	O
to	O
these	O
conditions	O
.	O

This	O
is	O
the	O
first	O
case	O
of	O
this	O
type	O
of	O
lung	B-DIS
cancer	I-DIS
the	O
same	O
of	O
the	O
first	O
description	O
in	O
the	O
literature	O
associated	O
with	O
HAM	O
outside	O
Japan	B-LOC
.	O

Hypertrophic	B-DIS
cardiomyopathy	I-DIS
HCM	I-DIS
is	O
a	O
myocardial	B-DIS
disease	I-DIS
characterized	O
by	O
left	O
ventricular	B-DIS
hypertrophy	I-DIS
not	O
solely	O
explained	O
by	O
abnormal	O
loading	O
conditions	O
.	O

Despite	O
its	O
rare	O
prevalence	B-EPI
in	O
pediatric	O
age	O
HCM	B-DIS
carries	O
a	O
relevant	O
risk	O
of	O
mortality	O
and	O
morbidity	O
in	O
both	O
infants	O
and	O
children	O
.	O

Pediatric	O
HCM	B-DIS
is	O
a	O
large	O
heterogeneous	O
group	O
of	O
disorders	O
.	O

Other	O
than	O
mutations	O
in	O
sarcomeric	O
genes	O
which	O
represent	O
the	O
most	O
important	O
cause	O
of	O
HCM	B-DIS
in	O
adults	O
childhood	O
HCM	B-DIS
includes	O
a	O
high	O
prevalence	B-EPI
of	O
non	O
-	O
sarcomeric	O
causes	O
including	O
inherited	O
errors	O
of	O
metabolism	O
i.e	O
.	O

glycogen	B-DIS
storage	I-DIS
diseases	I-DIS
lysosomal	O
storage	O
diseases	O
and	O
fatty	O
acid	O
oxidation	O
disorders	B-DIS
malformation	I-DIS
syndromes	I-DIS
neuromuscular	I-DIS
diseases	I-DIS
and	O
mitochondrial	B-DIS
disease	I-DIS
which	O
globally	O
represent	O
up	B-STAT
to	I-STAT
35	I-STAT
%	I-STAT
of	O
children	O
with	O
HCM	B-DIS
.	O

The	O
age	O
of	O
presentation	O
and	O
the	O
underlying	O
etiology	O
significantly	O
impact	O
the	O
prognosis	O
of	O
children	O
with	O
HCM	B-DIS
.	O

Moreover	O
in	O
recent	O
years	O
different	O
targeted	O
approaches	O
for	O
non	O
-	O
sarcomeric	O
etiologies	B-DIS
of	O
HCM	O
have	O
emerged	O
.	O

Therefore	O
the	O
etiological	O
diagnosis	O
is	O
a	O
fundamental	O
step	O
in	O
designing	O
specific	O
management	O
and	O
therapy	O
in	O
these	O
subjects	O
.	O

The	O
present	O
review	O
aims	O
to	O
provide	O
an	O
overview	O
of	O
the	O
non	O
-	O
sarcomeric	O
causes	B-DIS
of	O
HCM	O
in	O
children	O
focusing	O
on	O
the	O
pathophysiology	O
clinical	O
features	O
diagnosis	O
and	O
treatment	O
of	O
these	O
rare	O
disorders	O
.	O

West	B-LOC
Nile	I-LOC
virus	O
WNV	B-DIS
is	O
a	O
flavivirus	O
which	O
transmission	O
cycle	O
is	O
maintained	O
between	O
mosquitoes	O
and	O
birds	O
although	O
it	O
occasionally	O
causes	O
sporadic	O
outbreaks	O
in	O
horses	O
and	O
humans	O
that	O
can	O
result	O
in	O
serious	O
diseases	O
and	O
even	O
death	B-DIS
.	O

Since	O
its	O
first	O
isolation	O
in	O
Africa	B-LOC
in	O
1937	O
WNV	B-DIS
had	O
been	O
considered	O
a	O
neglected	O
pathogen	O
until	O
its	O
recent	O
spread	O
throughout	O
Europe	B-LOC
and	O
the	O
colonization	O
of	O
America	B-LOC
regions	O
where	O
it	O
continues	O
to	O
cause	O
outbreaks	O
with	O
severe	O
neurological	O
consequences	O
in	O
humans	O
and	O
horses	O
.	O

Although	O
our	O
knowledge	O
about	O
the	O
characteristics	O
and	O
consequences	O
of	O
the	O
virus	O
has	O
increased	O
enormously	O
lately	O
many	O
questions	O
remain	O
to	O
be	O
resolved	O
.	O

Here	O
we	O
thoroughly	O
update	O
our	O
knowledge	O
of	O
different	O
aspects	O
of	O
the	O
WNV	B-DIS
life	O
cycle	O
virology	O
and	O
molecular	O
classification	O
host	O
cell	O
interactions	O
transmission	O
dynamics	O
host	O
range	O
epidemiology	O
and	O
surveillance	O
immune	O
response	O
clinical	O
presentations	O
pathogenesis	O
diagnosis	O
prophylaxis	O
antivirals	O
and	O
vaccines	O
and	O
prevention	O
and	O
we	O
highlight	O
those	O
aspects	O
that	O
are	O
still	O
unknown	O
and	O
that	O
undoubtedly	O
require	O
further	O
investigation	O
.	O

Neonatal	O
herpes	B-DIS
simplex	I-DIS
virus	O
HSV	B-DIS
infection	I-DIS
is	O
rare	O
with	O
an	O
estimated	O
incidence	B-EPI
of	O
3.58	O
per	O
100000	O
live	O
births	O
in	O
the	O
UK	B-LOC
and	O
should	O
be	O
suspected	O
in	O
any	O
newborn	O
with	O
fever	B-DIS
and	O
bacterial	O
culture	O
-	B-DIS
negative	O
sepsis	O
.	O

We	O
describe	O
a	O
case	O
of	O
a	O
previously	O
well	O
full	O
-	O
term	O
male	O
neonate	O
who	O
presented	O
with	B-DIS
persistent	O
fever	O
and	O
elevated	O
ferritin	O
level	O
that	O
was	O
carried	O
out	O
during	O
the	O
era	O
of	O
the	O
COVID-19	O
pandemic	O
as	O
part	O
of	O
SARS	O
-	O
CoV-2	O
panel	O
investigations	O
.	O

Despite	O
the	O
initial	O
negative	O
HSV	O
serology	O
HSV-1	O
PCR	O
from	O
a	O
scalp	O
lesion	O
returned	O
positive	O
.	O

He	O
made	O
a	O
full	O
recovery	O
after	O
acyclovir	O
therapy	O
.	O

This	O
case	O
highlights	O
the	O
importance	O
of	O
maintaining	O
a	O
high	O
clinical	O
index	O
of	O
suspicion	O
of	O
HSV	B-DIS
infection	I-DIS
in	O
any	O
febrile	B-DIS
neonate	O
even	O
with	O
absence	O
of	O
maternal	O
history	O
and	O
negative	O
serology	O
particularly	O
if	O
associated	O
with	O
hyperferritinaemia	B-DIS
.	O

We	O
also	O
address	O
the	O
challenge	O
of	O
interpreting	O
inflammatory	O
biomarkers	O
'	O
results	O
for	O
SARS	B-DIS
-	I-DIS
CoV-2	O
infection	O
in	O
neonates	O
.	O

Stroke	B-DIS
is	O
a	O
leading	O
cause	O
of	O
disability	O
and	O
mortality	O
all	O
over	O
the	O
world	O
.	O

Due	O
to	O
an	O
aging	O
population	O
the	O
incidence	B-EPI
of	O
stroke	B-DIS
is	O
rising	O
significantly	O
which	O
has	O
led	O
to	O
devastating	O
consequences	O
for	O
patients	O
.	O

In	O
addition	O
to	O
traditional	O
risk	O
factors	O
such	O
as	O
age	O
hypertension	B-DIS
hyperlipidemia	I-DIS
diabetes	I-DIS
and	O
atrial	B-DIS
fibrillation	I-DIS
sleep	I-DIS
disorders	I-DIS
as	O
independent	O
modifiable	O
risk	O
factors	O
for	O
stroke	B-DIS
have	O
been	O
highlighted	O
increasingly	O
.	O

In	O
this	O
review	O
we	O
provide	O
an	O
overview	O
of	O
common	O
types	O
of	O
current	O
sleep	B-DIS
disturbances	I-DIS
in	O
cerebrovascular	B-DIS
diseases	I-DIS
including	O
insomnia	B-DIS
hypersomnia	I-DIS
breathing	I-DIS
-	I-DIS
related	I-DIS
sleep	O
disorders	B-DIS
and	O
parasomnias	O
.	O

Moreover	O
evidence	O
-	O
based	O
clinical	O
therapeutic	O
strategies	O
and	O
pitfalls	O
of	B-DIS
specific	I-DIS
sleep	O
disorders	B-DIS
after	O
stroke	O
are	O
discussed	O
.	O

We	O
also	O
review	O
the	O
neurobiological	O
mechanisms	O
of	O
these	O
treatments	O
as	O
well	O
as	O
their	O
effects	O
on	O
stroke	B-DIS
.	O

Since	O
depression	B-DIS
after	O
stroke	B-DIS
is	O
so	O
prevalent	O
and	O
closely	O
related	O
to	O
sleep	B-DIS
disorders	I-DIS
treatments	O
of	O
post	B-DIS
-	I-DIS
stroke	O
depression	O
are	O
also	O
briefly	O
mentioned	O
in	O
this	O
review	O
article	O
.	O

The	O
MBTPS2	B-DIS
gene	O
on	O
the	O
X	O
-	O
chromosome	O
encodes	O
the	O
membrane	O
-	O
bound	O
transcription	O
factor	O
protease	O
site-2	O
MBTPS2	O
or	O
site-2	O
protease	O
S2P	O
which	O
cleaves	O
and	O
activates	O
several	O
signaling	O
and	O
regulatory	O
proteins	O
from	O
the	O
membrane	O
.	O

The	O
MBTPS2	B-DIS
is	O
critical	O
for	O
a	O
myriad	O
of	O
cellular	O
processes	O
ranging	O
from	O
the	O
regulation	O
of	O
cholesterol	O
homeostasis	O
to	O
unfolded	O
protein	O
responses	O
.	O

While	O
its	O
functional	O
role	O
has	O
become	O
much	O
clearer	O
in	O
the	O
recent	O
years	O
how	O
mutations	O
in	O
the	O
MBTPS2	B-LOC
gene	O
lead	O
to	O
several	O
human	B-DIS
disorders	I-DIS
with	O
different	O
phenotypes	O
including	O
Ichthyosis	B-DIS
Follicularis	I-DIS
Atrichia	I-DIS
and	O
Photophobia	B-DIS
syndrome	I-DIS
IFAP	I-DIS
with	O
or	O
without	O
BRESHECK	O
syndrome	O
Keratosis	O
Follicularis	B-DIS
Spinulosa	O
Decalvans	B-DIS
KFSD	I-DIS
Olmsted	O
syndrome	O
and	O
Osteogenesis	B-DIS
Imperfecta	I-DIS
type	O
XIX	O
remains	O
obscure	O
.	O

This	O
review	O
presents	O
the	O
biological	O
role	O
of	O
MBTPS2	B-DIS
in	O
development	O
summarizes	O
its	O
mutations	O
and	O
implicated	O
disorders	O
and	O
discusses	O
outstanding	O
unanswered	O
questions	O
.	O

Abstract	O
Previous	O
studies	O
have	O
suggested	O
that	O
human	O
T	B-DIS
-	I-DIS
cell	O
leukemia	O
virus	O
type	O
1	O
HTLV-1	O
might	O
act	O
as	O
a	O
pathogen	B-DIS
in	I-DIS
rheumatoid	I-DIS
arthritis	O
RA	O
but	O
epidemiological	O
evidence	O
of	O
an	O
association	O
is	O
scarce	O
.	O

We	O
measured	O
anti	O
-	O
HTLV-1	O
antibodies	O
among	B-DIS
Nagasaki	I-DIS
atomic	O
bomb	O
survivors	O
to	O
determine	B-DIS
whether	O
HTLV-1	O
is	O
related	B-DIS
to	O
RA	O
and	O
whether	O
radiation	O
exposure	O
is	O
associated	O
with	O
HTLV-1	B-DIS
and	B-EPI
RA	O
prevalence	O
.	O
This	O
is	O
a	O
cross	O
-	B-DIS
sectional	I-DIS
study	O
among	O
atomic	O
bomb	O
survivors	O
who	O
participated	O
in	O
biennial	O
health	O
examinations	O
from	O
2006	O
to	O
2010	O
.	O

Serum	O
levels	O
of	O
anti	O
-	O
HTLV-1	O
antibodies	O
were	O
measured	O
using	O
a	O
chemiluminescent	O
enzyme	O
immunoassay	O
and	O
confirmed	O
by	O
Western	O
blotting	O
.	O

Association	O
between	O
HTLV-1	O
and	O
RA	B-DIS
was	O
analyzed	O
by	O
a	O
logistic	O
regression	O
model	O
.	O
Of	O
2091	O
participants	O
women	O
61.5	B-STAT
%	I-STAT
;	O
median	O
age	O
73	O
years	O
21510.3	B-STAT
%	I-STAT
had	O
anti	O
-	O
HTLV-1	O
antibodies	O
.	O

HTLV-1	O
prevalence	B-EPI
was	O
higher	O
among	O
women	O
13.1	B-STAT
%	I-STAT
vs	O
5.8	B-STAT
%	I-STAT
;	O
P	O
<	O
.001	O
.	O

Twenty	O
-	O
two	O
participants	O
1.1	B-STAT
%	I-STAT
were	O
diagnosed	B-DIS
with	O
RA	O
.	O

HTLV-1	O
prevalence	B-EPI
among	O
RA	B-DIS
participants	O
was	O
significantly	O
higher	O
than	O
that	O
among	O
non	O
-	O
RA	O
participants	O
27.3	B-STAT
%	I-STAT
vs	O
10.1	B-STAT
%	I-STAT
;	O
P	O
=	O
.020	O
.	O

After	O
adjustment	O
for	O
age	O
sex	O
and	O
hepatitis	B-DIS
C	I-DIS
virus	O
infection	O
HTLV-1	O
was	O
significantly	O
associated	O
with	O
prevalent	O
RA	O
odds	O
ratio	O
2.89	O
;	O
95	B-STAT
%	I-STAT
confidence	O
interval	O
1.06	O
7.03	O
.	O

There	O
was	O
no	O
association	O
between	O
radiation	O
dose	O
and	O
either	O
the	O
prevalence	B-EPI
of	O
HTLV-1	O
or	O
RA.This	O
study	O
among	O
a	O
well	O
-	O
defined	O
group	B-DIS
of	I-DIS
atomic	O
bomb	O
survivors	O
suggests	B-DIS
that	O
HTLV-1	O
is	O
associated	B-DIS
with	O
RA	O
.	O

Objective	O
To	O
determine	O
the	O
incidence	B-EPI
time	O
trends	O
risk	O
factors	O
and	O
severity	O
of	O
herpes	B-DIS
zoster	I-DIS
in	O
a	O
population	O
-	O
based	O
cohort	O
of	O
patients	O
with	O
newly	B-DIS
diagnosed	I-DIS
rheumatoid	I-DIS
arthritis	O
RA	O
compared	O
to	O
a	O
group	O
of	O
individuals	B-DIS
without	O
RA	O
from	O
the	O
same	O
population	O
.	O

Methods	O
All	O
residents	O
of	O
Olmsted	B-LOC
County	I-LOC
Minnesota	B-LOC
fulfilling	O
for	O
the	O
first	O
time	O
the	O
1987	O
American	O
College	O
of	O
Rheumatology	O
criteria	O
for	O
RA	B-DIS
between	O
January	O
11980	O
and	O
December	O
312007	O
and	O
a	O
cohort	O
of	O
similar	O
residents	O
without	O
RA	B-DIS
were	O
assembled	O
and	O
followed	O
by	O
retrospective	O
chart	O
review	O
until	O
death	B-DIS
migration	O
or	O
December	O
312008	O
.	O

Results	O
There	O
was	O
no	O
difference	O
in	O
the	O
presence	O
of	O
herpes	B-DIS
zoster	I-DIS
prior	O
to	O
the	O
RA	B-DIS
incidence	O
/	O
index	O
date	O
between	O
the	O
cohorts	O
P	O
=	O
0.85	O
.	O

During	O
followup	O
84	O
patients	O
with	O
RA	B-DIS
rate	O
12.1	O
cases	O
per	O
1000	O
person	O
-	O
years	O
and	O
44	O
subjects	B-DIS
without	O
RA	O
rate	O
5.4	O
cases	O
per	O
1000	O
person	B-DIS
-	I-DIS
years	O
developed	O
herpes	O
zoster	O
.	O

Patients	O
with	O
RA	B-DIS
were	O
more	O
likely	O
to	O
develop	O
herpes	B-DIS
zoster	I-DIS
than	O
those	O
without	O
RA	B-DIS
hazard	O
ratio	O
[	O
HR	O
]	O
2.4	O
[	O
95	B-STAT
%	I-STAT
confidence	O
interval	O
95	B-STAT
%	I-STAT
CI	O
1.7	O
-	O
3.5	O
]	O
.	O

Herpes	B-DIS
zoster	I-DIS
occurred	O
more	O
frequently	O
in	O
patients	O
diagnosed	O
with	O
RA	B-DIS
more	O
recently	O
HR	O
1.06	O
per	O
year	O
[	O
95	B-STAT
%	I-STAT
CI	O
1.02	O
-	O
1.10	O
]	O
.	O

Erosive	O
disease	O
previous	O
joint	O
surgery	O
and	O
use	O
of	O
hydroxychloroquine	O
and	O
corticosteroids	O
were	O
significantly	O
associated	O
with	O
the	O
development	O
of	O
herpes	B-DIS
zoster	I-DIS
in	O
RA	B-DIS
.	O

There	O
was	O
no	O
apparent	O
association	O
of	O
herpes	B-DIS
zoster	I-DIS
with	O
the	O
use	O
of	O
methotrexate	O
or	O
biologic	O
agents	O
.	O

Complications	O
of	O
herpes	B-DIS
zoster	I-DIS
occurred	O
at	O
a	O
similar	O
rate	O
in	O
both	O
cohorts	O
.	O

Conclusion	O
The	O
incidence	B-EPI
of	O
herpes	B-DIS
zoster	I-DIS
is	O
increased	O
in	O
RA	B-DIS
and	O
has	O
risen	O
in	O
recent	O
years	O
.	O

There	O
also	O
has	O
been	O
an	O
increasing	O
incidence	B-EPI
of	O
herpes	B-DIS
zoster	I-DIS
in	O
more	O
recent	O
years	O
in	O
the	O
general	O
population	O
.	O

RA	B-DIS
disease	I-DIS
severity	O
is	O
associated	O
with	O
the	O
development	O
of	O
herpes	B-DIS
zoster	I-DIS
.	O

Short	O
-	O
term	O
VEEG	O
represents	O
an	O
affordable	O
option	O
in	O
limited	O
resources	O
environments	O
.	O

There	O
are	O
few	O
reports	O
on	O
its	O
use	O
.	O

Its	O
diagnostic	O
yield	O
is	O
variable	O
7	B-STAT
-	I-STAT
57	I-STAT
%	I-STAT
and	O
can	O
be	O
related	O
to	O
the	O
differences	O
in	O
recording	O
time	O
.	O

The	O
present	O
study	O
analyzes	O
possible	O
predictive	O
factors	O
to	O
support	O
the	O
indication	O
of	O
a	O
short	O
-	O
term	O
VEEG	O
.	O

We	O
analyzed	O
short	O
-	O
term	O
VEEG	O
studies	O
<	O
24	O
h	O
throughout	O
a	O
period	O
of	O
5	O
years	O
2013	O
-	O
2017	O
.	O

The	O
patients	O
were	O
clustered	O
according	O
to	O
the	O
date	O
of	O
last	O
epileptic	B-DIS
seizure	I-DIS
and	O
the	O
frequency	O
of	O
epileptic	B-DIS
events	O
per	O
month	O
and	O
subcategorized	O
depending	O
on	O
the	O
frequency	O
found	O
.	O

Chi	O
square	O
univariate	O
analysis	O
was	O
performed	O
looking	O
for	O
predictive	O
variables	O
to	O
obtain	O
an	O
epileptic	B-DIS
short	O
-	O
term	O
EEG	O
.	O

A	O
multivariate	O
logistic	O
regression	O
analysis	O
was	O
performed	O
with	O
statistically	O
significant	O
variables	O
.	O

A	O
total	O
of	O
1092	O
VEEG	O
were	O
analyzed	O
from	O
832	O
patients	O
.	O

34.5	B-STAT
%	I-STAT
were	O
reported	O
as	O
epileptic	B-DIS
VEEG	O
.	O

In	O
the	O
multivariate	O
analysis	O
3	O
predictors	O
of	O
epileptic	B-DIS
short	O
-	O
term	O
VEEG	O
were	O
identified	O
The	O
use	O
of	O
2	O
or	O
more	O
antiepileptic	O
drugs	O
AEDs	O
OR	O
1.67	O
CI	O
1.23	B-STAT
-	I-STAT
2.25	I-STAT
p	O
=	O
0.001	O
the	O
presence	O
of	B-DIS
an	O
epileptic	O
event	O
in	O
the	O
last	O
month	O
OR	O
1.53	O
CI	O
1.07	O
-	O
2.17	O
p	O
=	O
0.018	O
and	B-DIS
daily	O
seizures	O
OR	O
1.84	O
CI	O
1.21	O
-	O
2.78	O
p	O
=	O
0.004	O
.	O

Six	O
-	B-DIS
month	O
seizure	O
free	O
subjects	O
predict	B-DIS
a	O
non	O
-	O
epileptic	O
VEEG	O
OR	O
0.58	O
CI	O
0.30	O
-	O
0.89	O
p	O
=	O
0.013	O
.	O

Friedreich	B-DIS
ataxia	I-DIS
FA	O
represents	O
the	O
most	O
frequent	O
type	O
of	O
inherited	O
ataxia	B-DIS
.	O

Most	O
patients	O
carry	O
homozygous	O
GAA	O
expansions	O
in	O
the	O
first	O
intron	O
of	O
the	O
frataxin	O
gene	O
on	O
chromosome	O
9	O
.	O

Due	O
to	O
epigenetic	O
alterations	O
frataxin	O
expression	O
is	O
significantly	O
reduced	O
.	O

Frataxin	O
is	O
a	O
mitochondrial	O
protein	O
.	O

Its	O
deficiency	O
leads	O
to	O
mitochondrial	O
iron	O
overload	O
defective	O
energy	O
supply	O
and	O
generation	O
of	O
reactive	O
oxygen	O
species	O
.	O

This	O
review	O
gives	O
an	O
overview	O
over	O
clinical	O
and	O
genetic	O
aspects	O
of	O
FA	O
and	O
discusses	O
current	O
concepts	O
of	O
frataxin	O
biogenesis	O
and	O
function	O
as	O
well	O
as	O
new	O
therapeutic	O
strategies	O
.	O

Background	O
and	O
aims	O
one	O
of	O
the	O
health	O
concerns	O
for	O
any	O
society	O
is	O
to	O
have	O
its	O
own	O
standard	O
of	O
growth	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
provide	O
the	O
age-	O
and	O
sex	O
-	O
specific	O
percentile	O
values	O
of	O
anthropometric	O
measures	O
for	O
adolescents	O
of	O
developing	O
countries	O
.	O

The	O
use	O
of	O
global	O
percentiles	O
in	O
developing	O
countries	O
overestimates	O
underweight	O
and	O
stunting	O
while	O
underestimates	O
overweight	O
and	O
obesity	B-DIS
.	O

Methods	O
The	O
data	O
were	O
obtained	O
from	O
the	O
Global	O
School	O
-	O
based	O
Student	O
Health	O
Survey	O
GSHS	O
.	O

This	O
study	O
was	O
conducted	O
on	O
school	O
students	O
selected	O
by	O
multistage	O
random	O
cluster	O
sampling	O
from	O
73	O
developing	O
countries	O
.	O

A	O
parametric	O
method	O
was	O
used	O
for	O
constructing	O
age	O
-	O
specific	O
reference	O
intervals	O
normal	O
ranges	O
.	O

Results	O
In	O
general	O
210045	O
11	O
-	O
18	O
years	O
-	O
old	O
schoolchildren	O
14.38	O
±	O
1.39	O
from	O
73	O
developing	O
countries	O
between	O
2003	O
and	O
2014	O
were	O
included	O
in	O
this	O
study	O
among	O
which	O
103080	O
49.08	B-STAT
%	I-STAT
were	O
male	O
and	O
106965	B-STAT
50.92	I-STAT
%	I-STAT
were	O
female	O
.	O

Calculation	O
of	O
body	O
mass	O
index	O
BMI	O
percentile	O
showed	O
that	O
for	O
all	O
BMI	O
percentile	O
curves	O
of	O
both	O
sexes	O
there	O
was	O
a	O
gradual	O
increase	O
up	O
to	O
the	O
age	O
of	O
around	O
15	O
years	O
and	O
then	O
remain	O
stable	O
except	O
for	O
95th	O
percentile	O
.	O

Moreover	O
in	O
all	O
weight	O
percentile	O
curves	O
of	O
boys	O
except	O
90th	O
and	O
above	O
there	O
was	O
a	O
slight	O
rise	O
until	O
the	O
age	O
of	O
18	O
years	O
.	O

In	O
10th	O
height	O
percentile	O
curves	O
and	O
above	O
in	O
boys	O
there	O
was	O
a	O
sharp	O
increase	O
up	O
to	O
the	O
age	O
of	O
17	O
followed	O
by	O
a	O
decline	O
.	O

Similarly	O
this	O
pattern	O
was	O
found	O
for	O
50th	O
height	O
percentile	O
and	O
above	O
in	O
girls	O
.	O

Conclusion	O
The	O
use	O
of	O
global	O
percentiles	O
in	O
developing	O
countries	O
overestimates	O
underweight	O
and	O
stunting	O
while	O
underestimates	O
overweight	O
and	O
obesity	B-DIS
.	O

Background	O
The	O
high	O
incidence	B-EPI
of	O
aortic	B-DIS
disease	I-DIS
in	O
subjects	O
with	O
congenital	B-DIS
aortic	I-DIS
valve	I-DIS
malformations	I-DIS
suggests	O
a	O
causative	O
relationship	O
between	O
these	O
2	O
conditions	O
.	O

The	O
histological	O
observation	O
in	O
aortic	O
dilatation	O
/	O
aneurysm	B-DIS
/	I-DIS
dissection	I-DIS
is	I-DIS
Erdheim	I-DIS
cystic	O
medial	B-DIS
necrosis	I-DIS
CMN	O
a	O
noninflammatory	O
loss	O
of	O
smooth	O
muscle	O
cells	O
SMCs	O
fragmentation	O
of	O
elastic	O
fibers	O
and	O
mucoid	O
degeneration	O
.	O

Methods	O
and	O
results	O
To	O
examine	O
whether	O
apoptosis	O
is	O
1	O
of	O
the	O
mechanisms	O
underlying	O
CMN	B-DIS
and	O
aortic	O
medial	O
layer	O
SMC	O
loss	O
ascending	O
aortic	O
wall	O
specimens	O
from	O
32	O
patients	O
were	O
collected	O
at	O
cardiothoracic	O
surgery	O
and	O
examined	O
by	O
histochemical	O
staining	O
and	O
terminal	O
deoxynucleotidyl	O
transferase	O
-	O
mediated	O
deoxyuridine	O
triphosphate	O
nick	O
end	O
labeling	O
.	O

From	O
echocardiography	O
results	O
4	O
groups	O
of	O
patients	O
were	O
identified	O
bicuspid	O
valve	O
carriers	O
with	O
bi	O
/	O
dil	O
or	O
without	O
bi/0	O
aortic	O
dilatation	O
and	O
tricuspid	O
valve	O
carriers	O
with	O
tri	O
/	O
dil	O
or	O
without	O
tri/0	O
aortic	O
dilatation	O
.	O

Massive	O
focal	O
apoptosis	O
was	O
observed	O
in	O
the	O
medial	O
layers	O
of	O
bi	O
/	O
dil	O
mean	O
apoptotic	O
index	O
[	O
mAI	B-STAT
]	O
8.1+/-6.0	O
and	O
tri	B-STAT
/	O
dil	O
mAI	O
8.1+/-8.3	O
compared	B-STAT
with	O
tri/0	O
mAI	O
0.9+/-1.2	O
;	O
P=0.0079	O
and	O
P=0.037	O
.	O

In	O
bi/0	O
mAI	O
9.1+/-5.7	B-STAT
compared	O
with	O
tri/0	O
mAI	O
0.9+/-1.2	B-STAT
rates	O
of	O
medial	O
SMC	O
apoptosis	O
were	O
increased	O
P=0.0025	O
.	O

Bi	O
/	O
dil	O
mean	O
age	O
40	O
.	O

6+/-15.7	B-STAT
years	O
were	O
significantly	O
younger	O
than	O
tri	O
/	O
dil	O
mean	B-STAT
age	O
56.4+/-12.8	O
years	O
undergoing	O
the	O
same	O
operation	O
P=0.0123	O
.	O

Conclusions	O
Premature	O
medial	O
layer	O
SMC	O
apoptosis	O
could	O
be	O
part	O
of	O
a	O
genetic	O
program	O
underlying	O
aortic	B-DIS
disease	I-DIS
in	O
patients	O
with	O
aortic	O
valve	B-DIS
malformations	I-DIS
.	O

Anticancer	O
drug	O
nephrotoxicity	B-DIS
is	O
an	O
important	O
and	O
increasing	O
adverse	O
drug	O
event	O
that	O
limits	O
the	O
efficacy	O
of	O
cancer	B-DIS
treatment	O
.	O

The	O
kidney	O
is	O
an	O
important	O
elimination	O
pathway	O
for	O
many	O
antineoplastic	O
drugs	O
and	O
their	O
metabolites	O
which	O
occurs	O
by	O
glomerular	O
filtration	O
and	O
tubular	O
secretion	O
.	O

Chemotherapeutic	O
agents	O
both	O
conventional	O
cytotoxic	O
agents	O
and	O
molecularly	O
targeted	O
agents	O
can	O
affect	O
any	O
segment	O
of	O
the	O
nephron	O
including	O
its	O
microvasculature	O
leading	O
to	O
many	O
clinical	O
manifestations	O
such	O
as	O
proteinuria	B-DIS
hypertension	I-DIS
electrolyte	I-DIS
disturbances	I-DIS
glomerulopathy	I-DIS
acute	O
and	O
chronic	O
interstitial	B-DIS
nephritis	I-DIS
acute	I-DIS
kidney	I-DIS
injury	I-DIS
and	O
at	O
times	O
chronic	B-DIS
kidney	I-DIS
disease	I-DIS
.	O

The	O
clinician	O
should	O
be	O
alert	O
to	O
recognize	O
several	O
factors	O
that	O
may	O
maximize	O
renal	B-DIS
dysfunction	I-DIS
and	O
contribute	O
to	O
the	O
increased	O
incidence	B-EPI
of	O
nephrotoxicity	B-DIS
associated	O
with	O
these	O
drugs	O
such	O
as	O
intravascular	O
volume	O
depletion	O
the	O
associated	O
use	O
of	O
nonchemotherapeutic	O
nephrotoxic	B-DIS
drugs	O
analgesics	O
antibiotics	O
proton	O
pump	O
inhibitors	O
and	O
bone	O
-	O
targeted	O
therapies	O
radiographic	O
ionic	O
contrast	O
media	O
or	O
radiation	B-DIS
therapy	I-DIS
urinary	I-DIS
tract	O
obstruction	B-DIS
and	I-DIS
intrinsic	I-DIS
renal	O
disease	O
.	O

Identification	O
of	O
patients	O
at	O
higher	O
risk	O
for	O
nephrotoxicity	B-DIS
may	O
allow	O
the	O
prevention	O
or	O
at	O
least	O
reduction	O
in	O
the	O
development	O
and	O
severity	O
of	O
this	O
adverse	O
effect	O
.	O

Therefore	O
the	O
aim	O
of	O
this	O
brief	O
review	O
is	O
to	O
provide	O
currently	O
available	O
evidences	O
on	O
oncologic	O
drug	O
-	B-DIS
related	O
nephrotoxicity	O
.	O

Since	O
2013	O
a	O
high	O
incidence	B-EPI
of	O
bilateral	O
symmetrical	O
alopecia	B-DIS
has	O
been	O
observed	O
in	O
free	O
-	O
ranging	O
Formosan	O
macaques	O
Macaca	O
cyclopis	O
in	O
Mt	B-LOC
.	O

Longevity	B-DIS
Taiwan	B-LOC
.	O

We	O
hypothesized	O
that	O
stress	O
induces	O
alopecia	B-DIS
in	O
this	O
population	O
.	O

To	O
verify	O
our	O
hypothesis	O
we	O
evaluated	O
the	O
histopathological	O
characteristics	O
of	O
skin	O
biopsy	O
and	O
used	O
a	O
validated	O
enzyme	O
immunoassay	O
EIA	O
for	O
fecal	O
glucocorticoid	O
metabolite	O
FGM	O
analysis	O
which	O
act	O
as	O
an	O
indicator	O
of	O
stress	O
experienced	O
by	O
the	O
individual	O
.	O

Follicular	O
densities	O
were	O
lower	O
2.1	O
-	O
3.0	O
mm	O
2	O
<	O
/s	O
in	O
individuals	O
with	O
symmetrical	O
alopecia	B-DIS
than	O
in	O
those	O
with	O
normal	O
hair	O
conditions	O
4.7	O
mm	O
2	O
<	O
/s	O
.	O

Furthermore	O
anagen	O
to	O
catagen	O
/	O
telogen	O
ratios	O
were	O
lower	O
in	O
individuals	B-DIS
with	O
alopecia	O
0	O
-	O
1.4	O
than	O
in	O
those	O
with	O
normal	O
hair	O
4.0	O
.	O

The	O
histopathological	O
characteristics	O
of	O
alopecia	B-DIS
were	O
similar	O
to	O
those	O
of	O
telogen	O
effluvium	O
which	O
indicates	O
that	O
stress	O
is	O
one	O
of	O
the	O
possible	O
etiologies	B-DIS
.	O

On	O
the	O
basis	O
of	O
the	O
analytical	O
and	O
biological	O
validation	O
of	O
EIAs	O
for	O
FGM	O
analysis	O
11β	O
-	O
hydroxyetiocholanolone	O
was	O
considered	O
suitable	O
for	O
monitoring	O
adrenocortical	O
activity	O
in	O
both	O
sexes	O
of	O
Formosan	O
macaques	O
.	O

The	O
mean	O
concentrations	O
standard	O
error	O
;	O
sample	O
size	O
of	O
11β	O
-	O
hydroxyetiocholanolone	O
were	O
2.02	O
0.17	O
;	O
n	O
=	O
10	O
and	O
1.41	O
0.10	O
;	O
n	O
=	O
31	O
μg	O
/	O
g	O
for	O
individuals	B-DIS
with	O
and	O
without	O
alopecia	O
respectively	O
.	O

Furthermore	O
the	O
results	O
of	O
logistic	O
regression	O
analysis	O
show	O
that	O
11β	O
-	O
hydroxyetiocholanolone	O
p	O
=	O
0.012	O
concentration	O
was	O
positively	O
associated	B-DIS
with	O
alopecia	O
.	O

Thus	O
stress	O
was	O
the	O
most	O
likely	O
to	O
trigger	O
symmetrical	O
alopecia	B-DIS
in	O
Formosan	O
macaques	O
in	O
Mt	B-LOC
.	O

Longevity	B-DIS
.	O

Although	O
stress	O
can	O
decrease	O
the	O
fitness	O
of	O
an	O
individual	O
considering	O
the	O
population	O
status	O
of	O
Formosan	O
macaques	O
in	O
Taiwan	B-LOC
is	O
stable	O
and	O
alopecia	B-DIS
was	O
only	O
observed	O
in	O
our	O
study	O
area	O
which	O
is	O
isolated	O
from	O
other	O
populations	O
the	O
impact	O
on	O
the	O
total	O
population	O
of	O
Formosan	O
macaque	O
in	O
Taiwan	B-LOC
is	O
limited	O
.	O

Nonetheless	O
stress	O
-	O
induced	O
immunosuppression	B-DIS
and	O
alopecia	O
might	O
affect	O
the	O
local	O
abundance	O
and	O
increase	O
zoonosis	O
risk	O
due	O
to	O
frequent	O
human	O
-	O
macaque	O
contact	O
in	O
Mt	B-LOC
.	O

Longevity	B-DIS
.	O

Future	O
studies	O
are	O
suggested	O
to	O
focus	O
on	O
the	O
causative	O
factor	O
of	O
stress	O
and	O
the	O
effects	O
of	O
stress	O
and	O
alopecia	B-DIS
on	O
the	O
health	O
and	O
welfare	O
in	O
the	O
Formosan	O
macaques	O
.	O

Background	O
It	O
has	O
been	O
estimated	O
that	O
27.8	O
million	O
neonates	O
will	O
die	O
worldwide	O
between	O
2018	O
and	O
2030	O
if	O
no	O
improvements	O
in	O
neonatal	O
and	O
maternal	O
care	O
take	O
place	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
rate	O
risk	O
factors	O
and	O
causes	O
of	O
neonatal	O
mortality	O
in	O
Jordan	B-LOC
.	O

Methods	O
In	O
August	O
2019	O
an	O
electronic	O
stillbirths	O
and	O
neonatal	O
deaths	B-DIS
surveillance	O
system	O
JSANDS	O
was	O
established	O
in	O
in	O
three	O
large	O
cities	O
through	O
five	O
hospitals	O
.	O

Data	O
on	O
all	O
births	O
neonatal	O
mortality	O
and	O
their	O
causes	O
and	O
other	O
characteristics	O
in	O
the	O
period	O
between	O
August	O
2019	O
and	O
January	O
2020	O
were	O
exported	O
from	O
the	O
JSANDS	O
and	O
analyzed	O
.	O

Results	O
A	O
total	O
of	O
10328	O
births	O
[	O
10226	O
live	O
births	O
LB	O
and	O
102	O
stillbirths	O
]	O
were	O
registered	O
in	O
the	O
study	O
period	O
with	O
a	O
rate	O
of	O
14.1	O
deaths	B-DIS
per	O
1000	O
LBs	O
;	O
76	B-STAT
%	I-STAT
were	O
early	O
neonatal	O
deaths	B-DIS
and	O
24	B-STAT
%	I-STAT
were	O
late	O
deaths	B-DIS
.	O

The	O
odds	O
of	O
deaths	B-DIS
in	O
the	O
Ministry	O
of	O
Health	O
hospitals	O
were	O
almost	O
21	O
times	O
OR	O
=	O
20.895	B-STAT
%	I-STAT
CI	O
2.8	O
153.1	O
higher	O
than	O
that	O
in	O
private	O
hospitals	O
.	O

Low	O
birthweight	O
and	O
pre	O
-	O
term	O
babies	O
were	O
significantly	O
more	O
likely	O
to	O
die	O
during	O
the	O
neonatal	O
period	O
compared	O
to	O
full	O
-	O
term	O
babies	O
.	O

The	O
odds	O
of	O
neonatal	O
mortality	O
were	O
significantly	O
higher	O
among	O
babies	O
born	O
to	O
housewives	O
compared	O
to	O
those	O
who	O
were	O
born	O
to	O
employed	O
women	O
OR	O
=	O
2.7	O
;	O
95	B-STAT
%	I-STAT
CI	O
1.2	O
6.0	O
.	O

Main	O
causes	O
of	O
neonatal	O
deaths	B-DIS
that	O
occurred	O
pre	O
-	O
discharge	B-DIS
were	I-DIS
respiratory	I-DIS
and	I-DIS
cardiovascular	O
disorders	O
43	B-STAT
%	I-STAT
and	O
low	O
birthweight	O
and	O
pre	O
-	O
term	O
33	B-STAT
%	I-STAT
.	O

The	O
main	O
maternal	O
conditions	O
that	O
attributed	O
to	O
these	O
deaths	B-DIS
were	O
complications	O
of	O
the	O
placenta	O
and	O
cord	O
complications	O
of	O
pregnancy	O
and	O
medical	O
and	O
surgical	O
conditions	O
.	O

The	O
main	O
cause	O
of	O
neonatal	O
deaths	B-DIS
that	O
occurred	O
post	O
-	O
discharge	O
were	O
low	O
birthweight	O
and	O
pre	O
-	O
term	O
42	B-STAT
%	I-STAT
.	O

Conclusions	O
The	O
rate	O
of	O
neonatal	O
mortality	O
have	O
not	O
decreased	O
since	O
2012	O
and	O
the	O
majority	O
of	O
neonatal	O
deaths	B-DIS
occurred	O
could	O
have	O
been	O
prevented	O
.	O

Regular	O
antenatal	O
visits	O
in	O
which	O
any	O
possible	O
diseases	O
or	O
complications	O
of	O
pregnant	O
women	O
or	O
fetal	O
anomalies	O
need	O
to	O
be	O
fully	O
documented	O
and	O
monitored	O
with	O
appropriate	O
and	O
timely	O
medical	O
intervention	O
to	O
minimize	O
such	O
deaths	B-DIS
.	O

Nonalcoholic	B-DIS
fatty	I-DIS
liver	I-DIS
disease	I-DIS
NAFLD	I-DIS
is	O
the	O
most	O
prevalent	O
liver	B-DIS
disease	I-DIS
worldwide	O
with	O
potential	O
causes	O
stemming	O
from	O
obesity	B-DIS
metabolic	B-DIS
syndrome	I-DIS
genetic	O
disorders	B-DIS
and	I-DIS
drug	I-DIS
toxicity	I-DIS
.	O

We	O
report	O
a	O
42	O
-	O
year	O
-	B-DIS
old	O
woman	B-DIS
with	O
lipodystrophy	O
and	O
NAFLD	O
due	O
to	O
a	O
pathogenic	O
variant	O
in	O
the	O
LMNA	O
D300N	O
gene	O
.	O

This	O
case	O
report	O
attempts	O
to	O
encourage	O
clinicians	O
to	O
consider	O
genetic	O
diseases	B-DIS
specifically	I-DIS
lipodystrophies	I-DIS
when	O
working	O
up	O
uncommon	O
causes	O
of	O
NAFLD	B-DIS
.	O

The	O
oral	B-DIS
-	I-DIS
facial	O
-	O
digital	O
syndrome	O
type	O
I	O
OFD	O
I	O
is	B-DIS
characterized	I-DIS
by	O
multiple	O
congenital	O
malformations	O
of	O
the	O
face	O
oral	O
cavity	O
and	O
digits	O
.	O

A	O
polycystic	B-DIS
kidney	I-DIS
disease	I-DIS
PKD	O
is	O
found	O
in	O
about	O
one	O
-	O
third	O
of	O
patients	O
but	O
long	O
-	O
term	O
outcome	O
and	O
complications	O
are	O
not	O
well	O
described	O
in	O
the	O
international	O
literature	O
.	O

Renal	O
findings	O
have	O
been	O
retrospectively	O
collected	O
in	O
a	O
cohort	O
of	O
34	O
females	O
all	O
carrying	O
a	O
pathogenic	O
mutation	O
in	O
the	O
OFD1	O
gene	O
with	O
ages	O
ranging	O
from	O
1	B-STAT
to	I-STAT
65	I-STAT
years	O
.	O

Twelve	O
patients	O
presented	O
with	O
PKD	O
-	O
11/1669	B-STAT
%	O
if	O
only	O
adults	O
were	O
considered	O
-with	O
a	O
median	O
age	O
at	O
diagnosis	O
of	O
29	O
years	O
[	O
IQR	O
interquartile	O
range	O
=	O
23.5	O
-	O
38	O
]	O
.	O

Among	O
them	O
10	O
also	O
presented	O
with	O
renal	B-DIS
impairment	I-DIS
and	O
6	O
were	O
grafted	O
median	O
age	O
=	O
38	O
years	O
[	O
IQR	O
=	O
25	O
-	O
48	O
]	O
.	O

One	O
grafted	O
patient	O
under	O
immunosuppressive	O
treatment	O
died	O
from	O
a	O
tumor	B-DIS
originated	O
from	O
a	O
native	O
kidney	O
.	O

The	O
probability	O
to	O
develop	O
renal	B-DIS
failure	I-DIS
was	O
estimated	O
to	O
be	O
more	B-STAT
than	I-STAT
50	I-STAT
%	I-STAT
after	O
the	O
age	O
of	O
36	O
years	O
.	O

Besides	O
neither	O
genotype	O
-	O
phenotype	O
correlation	O
nor	O
clinical	O
predictive	O
association	B-DIS
with	I-DIS
renal	O
failure	O
could	O
be	O
evidenced	O
.	O

These	O
data	O
reveal	O
an	O
unsuspected	O
high	O
incidence	B-EPI
rate	O
of	O
the	O
renal	B-DIS
impairment	I-DIS
outcome	O
in	O
OFD	B-DIS
I	I-DIS
syndrome	I-DIS
.	O

A	O
systematic	O
ultrasound	O
US	B-LOC
and	O
renal	O
function	O
follow	O
-	O
up	O
is	O
therefore	O
highly	O
recommended	O
for	B-DIS
all	I-DIS
OFD	O
I	O
patients	O
.	O

Impetigo	B-DIS
is	O
a	O
common	O
superficial	O
bacterial	B-DIS
infection	I-DIS
of	O
the	O
skin	O
with	O
a	O
global	O
disease	O
burden	O
of	O
greater	O
than	O
140	O
million	O
.	O

Children	O
are	O
more	O
affected	O
than	O
adults	O
and	O
incidence	B-EPI
decreases	O
with	O
age	O
.	O

Principal	O
pathogens	O
implicated	O
include	O
Staphylococcus	B-DIS
aureus	I-DIS
and	O
Streptococcus	O
pyogenes	O
.	O

There	O
are	O
two	O
common	O
variants	O
of	O
impetigo	O
nonbullous	O
70	B-STAT
%	I-STAT
and	O
bullous	O
30	B-STAT
%	I-STAT
.	O

Nonbullous	B-DIS
impetigo	I-DIS
is	O
caused	O
by	O
S.	B-DIS
aureus	I-DIS
and	O
S.	B-DIS
pyogenes	I-DIS
whereas	O
bullous	O
impetigo	O
is	O
caused	O
by	O
S.	B-DIS
aureus	I-DIS
.	O

The	O
classic	O
appearance	O
of	O
distinctive	O
honey	B-DIS
-	I-DIS
colored	I-DIS
crusted	O
legions	O
aids	O
in	O
diagnosis	O
which	O
is	O
most	O
often	O
based	O
on	O
clinical	O
presentation	O
.	O

The	O
disease	O
is	O
generally	O
mild	O
and	O
felt	O
to	O
be	O
self	O
-	O
limited	O
;	O
however	O
antimicrobial	O
treatment	O
is	O
often	O
initiated	O
to	O
reduce	O
spread	O
and	O
shorten	O
clinical	O
course	O
.	O

Treatment	O
for	O
limited	O
impetigo	B-DIS
is	O
topical	O
whereas	O
oral	O
therapy	O
is	O
recommended	O
for	O
extensive	O
cases	O
.	O

Rising	O
rates	O
of	O
bacterial	O
resistance	O
to	O
standard	O
treatment	O
regimens	O
should	O
inform	O
treatment	O
decisions	O
.	O

Complications	O
while	O
rare	O
can	O
occur	O
.	O

The	O
high	O
incidence	B-EPI
of	O
surgically	O
induced	O
heart	B-DIS
block	I-DIS
in	O
patients	O
with	O
levotransposition	O
of	O
the	O
great	O
arteries	O
is	O
now	O
better	O
understood	O
because	O
of	O
recent	O
anatomic	O
demonstration	O
of	O
an	O
unusual	O
anterior	O
location	O
of	O
the	O
atrioventricular	O
specialized	O
conducting	O
tissue	O
.	O

The	O
two	O
cases	O
reported	O
herein	O
proved	O
electrophysiologic	O
confirmation	O
of	O
this	O
previously	O
described	O
anatomy	O
.	O

The	O
specialized	O
conducting	O
bundle	O
was	O
easily	O
and	O
consistently	O
identified	O
and	O
then	O
avoided	O
in	O
successful	O
surgical	O
correction	O
in	O
one	O
patient	O
with	O
common	O
ventricle	O
type	O
A-3	O
and	O
in	O
another	O
with	O
corrected	O
transposition	O
large	O
ventricular	B-DIS
septal	I-DIS
defect	I-DIS
and	O
valvular	B-DIS
pulmonary	I-DIS
stenosis	I-DIS
.	O

Electrophysiologic	O
identification	O
of	O
the	O
atrioventricular	O
conduction	O
tissue	O
at	O
the	O
time	O
of	O
operation	O
may	O
decrease	O
the	O
incidence	B-EPI
of	O
heart	B-DIS
block	I-DIS
and	O
offers	O
additional	O
optimism	O
for	O
successful	O
correction	O
of	O
levotransposition	O
complexes	O
.	O

Juvenile	B-DIS
Idiopathic	I-DIS
Arthritis	I-DIS
is	O
one	O
of	O
the	O
most	O
prevalent	O
chronic	B-DIS
diseases	I-DIS
in	O
children	O
with	O
an	O
annual	O
incidence	B-EPI
of	O
2	O
-	O
20	O
cases	O
per	O
100000	O
and	O
a	O
prevalence	B-EPI
of	O
16	O
-	O
150	O
per	O
100000	O
.	O

It	O
is	O
associated	O
with	O
several	O
complications	O
that	O
can	O
cause	O
short	O
-	O
term	B-DIS
or	I-DIS
long	O
-	O
term	O
disability	O
and	O
reduce	O
the	O
quality	O
of	O
life	O
.	O

Among	O
these	O
growth	O
and	O
pubertal	O
disorders	O
play	O
an	O
important	O
role	O
.	O

Chronic	O
inflammatory	O
conditions	O
are	O
often	O
associated	O
with	O
growth	O
failure	O
ranging	O
from	O
slight	O
decrease	O
in	O
height	O
velocity	O
to	O
severe	O
forms	O
of	O
short	O
stature	B-DIS
.	O

The	O
prevalence	B-EPI
of	O
short	O
stature	B-DIS
in	O
JIA	B-DIS
varies	O
from	O
10.4	B-STAT
%	I-STAT
in	O
children	O
with	O
polyarticular	B-DIS
disease	I-DIS
to	O
41	B-STAT
%	I-STAT
of	O
patients	O
with	O
the	O
systemic	O
form	O
while	O
oligoarthritis	B-DIS
is	O
mostly	O
associated	O
with	O
localized	O
excessive	O
bone	O
growth	O
of	O
the	O
affected	O
limb	O
leading	O
to	O
limb	O
dissymmetry	O
.	O

The	O
pathogenesis	O
of	O
growth	O
disorders	O
is	O
multifactorial	O
and	O
includes	O
the	O
role	O
of	O
chronic	O
inflammation	O
long	O
-	O
term	O
use	O
of	O
corticosteroids	O
undernutrition	O
altered	O
body	O
composition	O
delay	O
of	O
pubertal	O
onset	O
or	O
slow	O
pubertal	O
progression	O
.	O

These	O
factors	O
can	O
exert	O
a	O
systemic	O
effect	O
on	O
the	O
GH	O
/	O
IGF-1	O
axis	O
and	O
on	O
the	O
GnRH	O
-	O
gonadotropin	O
-	O
gonadic	O
axis	O
or	O
a	O
local	O
influence	O
on	O
the	O
growth	O
plate	O
homeostasis	O
and	O
function	O
.	O

Although	O
new	O
therapeutic	O
options	O
are	O
available	O
to	O
control	O
inflammation	B-DIS
there	O
are	O
still	O
10	B-STAT
-	I-STAT
20	I-STAT
%	I-STAT
of	O
patients	O
with	O
severe	O
forms	O
of	O
the	O
disease	O
who	O
show	O
continuous	O
growth	O
impairment	O
ending	O
in	O
a	O
short	O
final	O
stature	O
.	O

Moreover	O
delayed	O
puberty	B-DIS
is	O
associated	O
with	O
a	O
reduction	O
in	O
the	O
peak	O
bone	O
mass	O
with	O
the	O
possibility	O
of	O
concomitant	O
or	O
future	O
bone	O
fragility	O
.	O

Monitoring	O
of	O
puberty	B-DIS
and	O
bone	O
health	O
is	O
essential	O
for	O
a	O
complete	O
health	O
assessment	O
of	O
adolescents	O
with	O
JIA	B-DIS
.	O

In	O
these	O
patients	O
an	O
assessment	O
of	O
the	O
pubertal	O
stage	O
every	O
6	O
months	O
from	O
the	O
age	O
of	O
9	O
years	O
is	O
recommended	O
.	O

Also	O
linear	O
growth	O
should	O
be	O
always	O
evaluated	O
considering	O
the	O
patient	O
's	O
bone	O
age	O
.	O

The	O
impact	O
of	O
rhGH	O
therapy	O
in	O
children	O
with	O
JIA	B-DIS
is	O
still	O
unclear	O
but	O
it	O
has	O
been	O
shown	O
that	O
if	O
rhGH	O
is	O
added	O
at	O
high	O
dose	O
in	O
a	O
low	O
-	O
inflammatory	O
condition	O
post	O
steroids	O
and	O
on	O
biologic	O
therapy	O
it	O
is	O
able	O
to	O
favor	O
a	O
prepubertal	O
growth	O
acceleration	O
comparable	O
with	O
the	O
catch	O
-	O
up	B-DIS
growth	O
response	O
in	O
GH	O
-	O
deficient	O
patients	O
.	O

Here	O
we	O
provide	O
a	O
comprehensive	O
review	O
of	O
the	O
pathogenesis	O
of	O
puberty	B-DIS
and	O
growth	O
disorders	O
in	O
children	O
with	O
JIA	B-DIS
which	O
can	O
help	O
the	O
pediatrician	O
to	O
properly	O
and	O
timely	O
assess	O
the	O
presence	O
of	O
growth	O
and	O
pubertal	O
disorders	O
in	O
JIA	B-DIS
patients	O
.	O

Background	O
Plague	O
is	O
a	O
re	O
-	O
emerging	B-DIS
flea	I-DIS
-	O
borne	O
infectious	O
disease	O
of	O
global	O
importance	O
and	O
in	O
recent	O
years	O
Zambia	B-LOC
has	B-EPI
periodically	O
experienced	O
increased	O
incidence	O
of	O
outbreaks	O
of	O
this	O
disease	O
.	O

However	O
there	O
are	O
currently	O
no	O
studies	O
in	O
the	O
country	O
that	O
provide	O
a	O
quantitative	O
assessment	O
of	O
the	O
ability	O
of	O
the	O
disease	O
to	O
spread	O
during	O
these	O
outbreaks	O
.	O

This	O
limits	O
our	O
understanding	O
of	O
the	O
epidemiology	O
of	O
the	O
disease	O
especially	O
for	O
planning	O
and	O
implementing	O
quantifiable	O
and	O
cost	O
-	O
effective	O
control	O
measures	O
.	O

To	O
fill	O
this	O
gap	O
the	O
basic	O
reproduction	O
number	O
R0	O
for	O
bubonic	O
plague	O
was	O
estimated	O
in	O
this	O
study	O
using	O
data	O
from	O
the	O
2015	O
Nyimba	O
district	O
outbreak	O
in	O
the	O
Eastern	O
province	O
of	O
Zambia	B-LOC
.	O

R0	O
is	O
the	O
average	O
number	O
of	O
secondary	O
infections	B-DIS
arising	O
from	O
a	O
single	O
infectious	O
individual	O
during	O
their	O
infectious	O
period	O
in	O
an	O
entirely	O
susceptible	O
population	O
.	O

Methodology	O
/	O
principal	O
findings	O
Secondary	O
epidemic	O
data	O
for	O
the	O
most	O
recent	O
2015	O
Nyimba	B-DIS
district	I-DIS
bubonic	O
plague	O
outbreak	O
in	O
Zambia	B-LOC
was	O
analyzed	O
.	O

R0	O
was	O
estimated	O
as	O
a	O
function	O
of	O
the	O
average	O
epidemic	O
doubling	O
time	O
based	O
on	O
the	O
initial	O
exponential	O
growth	O
rate	O
of	O
the	O
outbreak	O
and	O
the	O
average	O
infectious	O
period	O
for	O
bubonic	B-DIS
plague	I-DIS
.	O

R0	O
was	O
estimated	O
to	O
range	O
between	O
1.5599	O
[	O
95	B-STAT
%	I-STAT
CI	O
1.382	O
-	O
1.7378	O
]	O
and	O
1.9332	O
[	O
95	B-STAT
%	I-STAT
CI	O
1.6366	O
-	O
2.2297	O
]	O
with	O
average	O
of	O
1.7465	O
[	O
95	B-STAT
%	I-STAT
CI	O
1.5093	O
-	O
1.9838	O
]	O
.	O

Further	O
an	O
SIR	O
deterministic	O
mathematical	O
model	O
was	O
derived	O
for	O
this	O
infection	B-DIS
and	O
this	O
estimated	O
R0	O
to	O
be	O
between	O
1.4	O
to	O
1.5	O
which	O
was	O
within	O
the	O
range	O
estimated	O
above	O
.	O

Conclusions	O
/	O
significance	O
This	O
estimated	O
R0	O
for	O
bubonic	O
plague	O
is	O
an	O
indication	O
that	O
each	O
bubonic	O
plague	O
case	O
can	O
typically	O
give	O
rise	O
to	O
almost	O
two	O
new	O
cases	O
during	O
these	O
outbreaks	O
.	O

This	O
R0	O
estimate	O
can	O
now	O
be	O
used	O
to	O
quantitatively	O
analyze	O
and	O
plan	O
measurable	O
interventions	O
against	O
future	O
plague	O
outbreaks	O
in	O
Zambia	B-LOC
.	O

Little	O
information	O
is	O
available	O
on	O
the	O
prevalences	B-EPI
of	O
birth	B-DIS
defects	I-DIS
in	O
Korea	B-LOC
.	O

The	O
aims	O
of	O
this	O
study	O
were	O
to	O
estimate	O
recent	O
prevalences	B-EPI
of	O
selected	O
birth	B-DIS
defects	I-DIS
and	O
to	O
analyze	O
the	O
prevalence	B-EPI
trends	O
of	O
these	O
defects	O
during	O
the	O
period	O
from	O
2008	O
to	O
2014	O
.	O

Prevalences	B-EPI
were	O
calculated	O
for	O
69	O
major	O
birth	B-DIS
defects	I-DIS
using	O
health	O
insurance	O
claim	O
data	O
obtained	O
from	O
the	O
Korea	O
National	O
Health	O
Insurance	O
Service	O
NHIS	O
.	O

Prevalence	B-EPI
rate	O
ratios	O
were	O
calculated	O
using	O
Poisson	O
regression	O
to	O
analyze	O
trends	O
over	O
the	O
7	O
-	O
year	O
study	O
period	O
.	O

The	O
overall	O
prevalence	B-EPI
of	O
a	O
major	O
birth	B-DIS
defect	I-DIS
was	O
446.3	O
per	O
10000	O
births	O
95	B-STAT
%	I-STAT
CI	O
444.0⁻448.6	O
;	O
470.9	O
per	O
10000	O
births	O
95	B-STAT
%	I-STAT
CI	O
467.6⁻474.2	O
for	O
males	O
and	O
420.2	O
per	O
10000	O
births	O
95	B-STAT
%	I-STAT
CI	O
417⁻423.4	O
for	O
females	O
.	O

The	O
prevalence	B-EPI
rates	O
of	O
the	O
most	O
common	O
birth	B-DIS
defects	I-DIS
over	O
the	O
study	O
period	O
were	O
;	O
septal	O
defect	O
138.2	O
per	O
10000	O
;	O
95	B-STAT
%	I-STAT
CI	O
136.9⁻139.5	O
congenital	B-DIS
hip	I-DIS
dislocation	I-DIS
652	O
per	O
10000	O
;	O
95	B-STAT
%	I-STAT
CI	O
64.1⁻65.9	O
and	O
ventricular	B-DIS
septal	I-DIS
defect	I-DIS
62.62	I-DIS
per	I-DIS
10000	I-DIS
;	O
95	B-STAT
%	I-STAT
CI	O
61.7⁻63.5	O
.	O

During	O
the	O
study	O
period	O
a	O
significant	O
increase	O
in	O
the	O
prevalence	B-EPI
of	O
a	O
major	O
birth	B-DIS
defect	I-DIS
was	O
observed	O
with	O
a	O
prevalence	B-EPI
rate	O
ratio	O
PRR	O
of	O
1.091	O
.	O

The	O
strongest	O
trend	O
was	O
observed	O
for	O
renal	B-DIS
dysplasia	I-DIS
which	O
had	O
a	O
PRR	O
of	O
1.27595	B-STAT
%	I-STAT
CI	O
1.211⁻1.343	O
and	O
upward	O
trends	O
were	O
observed	O
for	O
urogenital	B-DIS
anomalies	I-DIS
such	O
as	O
renal	B-DIS
agenesis	I-DIS
PRR	O
1.10295	B-STAT
%	I-STAT
CI	O
1.067⁻1.138	O
undescended	B-DIS
testis	I-DIS
PRR	O
1.08295	B-STAT
%	I-STAT
CI	O
1.072⁻1.093	O
and	O
hypospadias	B-DIS
PRR	O
1.06795	B-STAT
%	I-STAT
CI	O
1.044⁻1.090	O
.	O

This	O
study	O
shows	O
an	O
overall	O
increase	O
in	O
the	O
prevalences	B-EPI
of	O
birth	B-DIS
defects	I-DIS
including	O
hypospadias	B-DIS
and	O
undescended	B-DIS
testis	I-DIS
which	O
are	O
known	O
to	O
be	O
associated	O
with	O
endocrine	O
factors	O
.	O

In	O
the	O
future	O
standardized	O
birth	B-DIS
defect	I-DIS
registries	O
should	O
be	O
established	O
to	O
enable	O
these	O
trends	O
to	O
be	O
monitored	O
.	O

Neurodegeneration	O
with	O
brain	O
iron	O
accumulation	O
NBIA	B-DIS
is	O
a	O
group	O
of	O
rare	O
neurogenetic	B-DIS
degenerative	I-DIS
diseases	I-DIS
caused	O
by	O
genetic	O
mutations	O
and	O
characterized	O
by	O
iron	O
deposition	O
in	O
the	O
central	O
nervous	O
system	O
especially	O
in	O
the	O
basal	O
ganglia	O
with	O
an	O
overall	O
incidence	B-EPI
rate	O
of	O
2/1000	B-STAT
000	O
-	O
3/1000	B-STAT
000	O
.	O

Major	O
clinical	O
manifestations	O
are	O
extrapyramidal	B-DIS
symptoms	I-DIS
.	O

This	O
disease	O
is	O
presently	O
classified	O
into	O
14	O
different	O
subtypes	O
based	O
on	O
different	O
pathogenic	O
genes	O
and	O
its	O
pathogenesis	O
and	O
treatment	O
remain	O
unclear	O
.	O

This	O
article	O
summarizes	O
the	O
research	O
advances	O
in	O
the	O
pathogenesis	O
and	O
treatment	O
of	O
NBIA	B-DIS
so	O
as	O
to	O
help	O
pediatricians	O
understand	O
this	O
disease	O
and	O
provide	O
a	O
reference	O
for	O
subsequent	O
research	O
on	O
treatment	O
.	O

Congenital	B-DIS
hearing	I-DIS
loss	I-DIS
is	O
the	O
most	O
common	O
birth	B-DIS
defect	I-DIS
estimated	O
to	O
affect	O
2	O
-	O
3	O
in	O
every	O
1000	O
births	O
.	O

Currently	O
there	O
is	O
no	O
cure	O
for	O
hearing	B-DIS
loss	I-DIS
.	O

Treatment	O
options	O
are	O
limited	O
to	O
hearing	O
aids	O
for	O
mild	O
and	O
moderate	O
cases	O
and	O
cochlear	O
implants	O
for	O
severe	O
and	O
profound	O
hearing	B-DIS
loss	I-DIS
.	O

Here	O
we	O
provide	O
a	O
literature	O
overview	O
of	O
the	O
environmental	O
and	O
genetic	O
causes	O
of	O
congenital	B-DIS
hearing	I-DIS
loss	I-DIS
common	O
animal	O
models	O
and	O
methods	O
used	O
for	O
hearing	O
research	O
as	O
well	O
as	O
recent	O
advances	O
towards	O
developing	O
therapies	O
to	O
treat	O
congenital	B-DIS
deafness	I-DIS
.	O

©	O
2021	O
The	O
Authors	O
.	O

Enshi	O
prefecture	O
of	O
Hubei	B-LOC
Province	I-LOC
is	O
well	O
known	O
for	O
human	O
selenium	O
Se	O
poisoning	O
in	O
the	O
early	O
1960s	O
in	O
China	B-LOC
.	O

Sporadic	O
cases	O
of	O
Se	B-DIS
poisoning	I-DIS
in	O
livestocks	O
are	O
still	O
being	O
found	O
.	O

In	O
this	O
study	O
Se	O
levels	O
in	O
water	O
cropland	O
soils	O
and	O
various	O
crops	O
from	O
high	O
-	O
Se	O
areas	O
of	O
Enshi	O
were	O
measured	O
to	O
investigate	O
the	O
distribution	O
and	O
bioavailability	O
of	O
Se	O
in	O
the	O
environments	O
as	O
well	O
as	O
probable	O
daily	O
intake	O
PDI	O
of	O
Se	O
for	O
local	O
residents	O
.	O

The	O
total	O
Se	O
in	O
surface	O
water	O
ranged	O
from	O
2.0	O
to	O
519.3μg	B-STAT
/	O
L	O
with	O
a	O
geometric	O
mean	O
of	O
46.0±127.8	O
μg	O
/	O
L	O
n=48	O
70.5	O
-	O
99.5	O
%	O
of	O
which	O
was	O
present	O
in	O
the	O
form	O
of	O
Se	O
VI	O
.	O

The	O
soil	O
Se	O
concentration	O
varied	O
from	O
2.89	O
to	O
87.3	O
μg	O
/	O
g	O
with	O
a	O
geometric	O
mean	O
of	O
9.36±18.6	O
μg	O
/	O
g	O
n=45	O
and	O
most	O
of	O
Se	B-DIS
was	I-DIS
associated	I-DIS
with	O
organic	O
matter	O
OM	O
-	O
Se	O
.	O

The	O
total	O
Se	O
in	O
rice	O
corn	O
and	O
vegetable	O
samples	O
were	O
2.11±2.87	O
μg	O
/	O
g	O
n=21	O
3.76±11.6	O
μg	O
/	O
g	O
n=16	O
and	O
2.09±3.38	O
μg	O
/	O
g	O
n=25	O
respectively	O
.	O

Stream	O
water	O
Se	O
is	O
likely	O
leached	O
from	O
carbonaceous	O
shale	O
and	O
mine	O
wastes	O
leading	O
to	O
Se	O
accumulation	O
in	O
paddy	O
soils	O
.	O

OM	O
-	O
Se	O
may	O
play	O
an	O
important	O
role	O
in	O
Se	O
uptake	O
by	O
rice	O
plant	O
in	O
high	O
-	O
Se	O
area	O
of	O
Enshi	O
.	O

The	O
PDI	O
of	O
Se	O
is	O
approximately	O
2144	O
μg	O
/	O
day	O
and	O
Se	O
concentration	O
in	O
blood	O
is	O
estimated	O
at	O
about	O
3248	O
μg	O
/	O
L	O
posing	O
a	O
potential	O
chronic	O
Se	O
poisoning	O
risk	O
to	O
local	O
residents	O
.	O

Cereal	O
consumption	O
48.5	B-STAT
%	I-STAT
makes	O
a	O
great	O
contribution	O
to	O
human	O
daily	O
Se	O
intake	O
followed	O
by	O
vegetables	O
36.6	B-STAT
%	I-STAT
meats	O
8.5	B-STAT
%	I-STAT
and	O
drinking	O
water	O
6.4	B-STAT
%	I-STAT
.	O

However	O
when	O
assessing	O
health	O
risk	O
on	O
human	O
in	O
high	O
-	O
Se	O
areas	O
the	O
contribution	O
of	O
drinking	O
water	O
to	O
daily	O
Se	O
intake	O
can	O
not	O
be	O
ignored	O
due	O
to	O
high	O
Se	O
content	O
and	O
dominant	O
Se	O
VI	O
species	O
.	O

Local	O
inhabitants	O
should	O
be	O
advised	O
not	O
to	O
grow	O
crops	O
in	O
high	O
-	O
Se	O
lands	O
or	O
irrigate	O
using	O
high	O
-	O
Se	O
water	O
.	O

If	O
possible	O
they	O
should	O
drink	O
pipe	O
water	O
and	O
consume	O
foods	O
mixed	O
with	O
those	O
from	O
outside	O
the	O
high	O
-	O
Se	O
areas	O
.	O

Introduction	O
Limited	O
data	O
are	O
available	O
on	O
the	O
incidence	B-EPI
of	O
primary	B-DIS
ophthalmic	I-DIS
cancers	I-DIS
worldwide	O
.	O

We	O
describe	O
the	O
incidence	B-EPI
and	O
trends	O
of	O
primary	B-DIS
ophthalmic	I-DIS
cancers	I-DIS
in	O
Singapore	B-LOC
.	O

Methods	O
Data	O
on	O
ophthalmic	O
cancers	B-DIS
diagnosed	O
in	O
Singapore	B-LOC
from	O
1996	O
to	O
2016	O
were	O
retrieved	O
from	O
the	O
Singapore	O
Cancer	B-DIS
Registry	O
for	O
analysis	O
.	O

All	O
were	O
histologically	O
proven	O
primary	B-DIS
ophthalmic	I-DIS
cancers	I-DIS
.	O

Calculations	O
of	O
incidence	B-EPI
and	O
age	O
-	O
specific	O
frequency	O
of	B-DIS
ophthalmic	O
malignancy	O
were	O
made	O
.	O

Results	O
A	O
total	O
of	O
297	O
cases	O
were	O
included	O
with	O
males	O
constituting	O
59.9	B-STAT
%	I-STAT
.	O

The	O
race	O
distribution	O
was	O
78.5	B-STAT
%	I-STAT
Chinese	O
16.5	B-STAT
%	I-STAT
Malay	O
3.7	B-STAT
%	I-STAT
Indians	O
and	O
1.3	B-STAT
%	I-STAT
others	O
.	O

There	O
was	O
an	O
overall	O
increase	O
in	O
ophthalmic	O
malignancies	O
.	O

The	O
mean	O
age	O
of	O
onset	O
was	O
47.4	O
years	O
.	O

The	O
most	O
common	O
cancers	B-DIS
were	O
retinoblastoma	B-DIS
93.3	B-STAT
%	I-STAT
in	O
patients	O
younger	O
than	O
15	O
years	O
and	O
lymphoma	O
71.3	B-STAT
%	I-STAT
in	O
patients	O
aged	O
15	O
years	O
and	O
older	O
.	O

There	O
has	O
been	O
an	O
increase	O
in	O
lymphomas	B-DIS
from	O
16.7	B-STAT
%	I-STAT
in	O
1968	O
-	O
1995	O
to	O
71.3	B-STAT
%	I-STAT
in	O
1996	O
-	O
2016	O
in	O
those	O
aged	O
15	O
years	O
and	O
older	O
.	O

The	O
most	O
common	O
types	O
of	O
ophthalmic	O
cancer	O
according	O
to	O
location	O
are	O
lymphoma	O
of	O
the	O
orbit	O
conjunctiva	O
cornea	O
and	O
lacrimal	O
gland	O
;	O
retinoblastoma	B-DIS
of	O
the	O
retina	O
;	O
and	O
malignant	B-DIS
melanoma	I-DIS
of	O
the	O
choroid	O
and	O
ciliary	O
body	O
.	O

Conclusion	O
Our	O
study	O
reported	O
the	O
incidence	B-EPI
and	O
trends	O
of	O
ophthalmic	O
cancer	O
in	O
the	O
Singapore	B-LOC
population	O
and	O
showed	O
an	O
overall	O
increase	O
in	O
ophthalmic	O
malignancies	O
in	O
Singapore	B-LOC
from	O
1996	O
-	O
2016	O
.	O

A	O
substantial	O
increase	O
in	O
lymphomas	B-DIS
over	O
the	O
last	O
2	O
decades	O
was	O
noted	O
.	O

The	O
data	O
could	O
aid	O
clinicians	O
epidemiologists	O
and	O
policymakers	O
in	O
implementing	O
strategies	O
to	O
address	O
trends	O
in	O
ophthalmic	O
cancers	B-DIS
and	O
spur	O
aetiological	O
research	O
to	O
improve	O
quality	O
of	O
life	O
in	O
patients	O
with	O
such	O
cancers	B-DIS
.	O

Rifampicin	O
discovered	O
more	O
than	O
50	O
years	O
ago	O
represents	O
the	O
last	O
novel	O
class	O
of	O
antibiotics	O
introduced	O
for	O
the	O
first	O
-	O
line	O
treatment	B-DIS
of	O
tuberculosis	O
.	O

Drugs	O
in	O
this	O
class	O
form	O
part	O
of	O
a	O
6	O
-	O
month	O
regimen	O
that	O
is	O
ineffective	O
against	O
MDR	O
and	O
XDR	O
TB	O
and	O
incompatible	O
with	O
many	O
antiretroviral	O
drugs	O
.	O

Investments	O
in	O
R	O
&	O
D	O
strategies	O
have	O
increased	O
substantially	O
in	O
the	O
last	O
decades	O
.	O

However	O
the	O
number	O
of	O
new	O
drugs	O
approved	O
by	O
drug	O
regulatory	O
agencies	O
worldwide	O
does	O
not	O
increase	O
correspondingly	O
.	O

Ruthenium	O
complexes	O
SCAR	O
have	O
been	O
tested	O
in	O
our	O
laboratory	O
and	O
showed	O
promising	O
activity	O
against	O
Mycobacterium	O
tuberculosis	O
.	O

These	O
complexes	O
showed	O
up	O
to	O
150	O
times	O
higher	O
activity	O
against	O
MTB	O
than	O
its	O
organic	O
molecule	O
without	O
the	O
metal	O
free	O
ligand	O
with	O
low	O
cytotoxicity	O
and	O
high	O
selectivity	O
.	O

In	O
this	O
study	O
promising	O
results	O
inspired	O
us	O
to	O
seek	O
a	O
better	O
understanding	O
of	O
the	O
biological	O
activity	O
of	O
these	O
complexes	O
.	O

The	O
in	O
vitro	O
biological	O
results	O
obtained	O
with	O
the	O
SCAR	O
compounds	O
were	O
extremely	O
promising	O
comparable	O
to	O
or	O
better	O
than	O
those	O
for	O
first	O
-	O
line	O
drugs	O
and	O
drugs	O
in	O
development	O
.	O

Moreover	O
SCAR	O
1	B-STAT
and	I-STAT
4	I-STAT
which	O
presented	O
low	O
acute	O
toxicity	B-DIS
were	O
assessed	O
by	O
Ames	O
test	O
and	O
results	O
demonstrated	O
absence	O
of	O
mutagenicity	O
.	O

VACTERL	O
/	O
VATER	O
association	O
is	O
typically	O
defined	O
by	O
the	O
presence	O
of	O
at	O
least	O
three	O
of	O
the	B-DIS
following	I-DIS
congenital	O
malformations	O
vertebral	B-DIS
defects	I-DIS
anal	I-DIS
atresia	I-DIS
cardiac	O
defects	B-DIS
tracheo	I-DIS
-	I-DIS
esophageal	O
fistula	O
renal	O
anomalies	O
and	O
limb	O
abnormalities	O
.	O

In	O
addition	O
to	O
these	O
core	O
component	O
features	O
patients	O
may	O
also	O
have	O
other	O
congenital	B-DIS
anomalies	I-DIS
.	O

Although	O
diagnostic	O
criteria	O
vary	O
the	O
incidence	B-EPI
is	O
estimated	O
at	O
approximately	O
1	B-STAT
in	I-STAT
10000	I-STAT
to	O
1	B-STAT
in	I-STAT
40000	I-STAT
live	O
-	O
born	O
infants	O
.	O

The	O
condition	O
is	O
ascertained	O
clinically	O
by	O
the	O
presence	O
of	O
the	O
above	O
-	O
mentioned	O
malformations	O
;	O
importantly	O
there	O
should	O
be	O
no	O
clinical	O
or	O
laboratory	O
-	O
based	O
evidence	O
for	O
the	O
presence	O
of	O
one	O
of	O
the	O
many	O
similar	O
conditions	O
as	O
the	O
differential	O
diagnosis	O
is	O
relatively	O
large	O
.	O

This	O
differential	O
diagnosis	O
includes	O
but	O
is	O
not	O
limited	O
to	O
Baller	B-DIS
-	I-DIS
Gerold	I-DIS
syndrome	I-DIS
CHARGE	I-DIS
syndrome	I-DIS
Currarino	O
syndrome	B-DIS
deletion	I-DIS
22q11.2	I-DIS
syndrome	I-DIS
Fanconi	I-DIS
anemia	I-DIS
Feingold	I-DIS
syndrome	I-DIS
Fryns	I-DIS
syndrome	O
MURCS	B-DIS
association	I-DIS
oculo	I-DIS
-	I-DIS
auriculo	I-DIS
-	I-DIS
vertebral	I-DIS
syndrome	I-DIS
Opitz	I-DIS
G	O
/	O
BBB	O
syndrome	B-DIS
Pallister	O
-	O
Hall	O
syndrome	O
Townes	O
-	O
Brocks	O
syndrome	O
and	O
VACTERL	O
with	O
hydrocephalus	O
.	O

Though	O
there	O
are	O
hints	O
regarding	O
causation	O
the	O
aetiology	O
has	O
been	O
identified	O
only	O
in	O
a	O
small	O
fraction	O
of	O
patients	O
to	O
date	O
likely	O
due	O
to	O
factors	O
such	O
as	O
a	O
high	O
degree	O
of	O
clinical	O
and	O
causal	O
heterogeneity	O
the	O
largely	O
sporadic	O
nature	O
of	O
the	O
disorder	O
and	O
the	O
presence	O
of	O
many	O
similar	O
conditions	O
.	O

New	O
genetic	O
research	O
methods	O
offer	O
promise	O
that	O
the	O
causes	O
of	O
VACTERL	O
association	O
will	O
be	O
better	O
defined	O
in	O
the	O
relatively	O
near	O
future	O
.	O

Antenatal	O
diagnosis	O
can	O
be	O
challenging	O
as	O
certain	O
component	O
features	O
can	O
be	O
difficult	O
to	O
ascertain	O
prior	O
to	O
birth	O
.	O

The	O
management	O
of	O
patients	O
with	O
VACTERL	O
/	O
VATER	O
association	O
typically	O
centers	O
around	O
surgical	O
correction	O
of	O
the	B-DIS
specific	I-DIS
congenital	O
anomalies	B-DIS
typically	I-DIS
anal	O
atresia	O
certain	O
types	B-DIS
of	I-DIS
cardiac	O
malformations	B-DIS
and/or	I-DIS
tracheo	O
-	O
esophageal	O
fistula	O
in	O
the	O
immediate	O
postnatal	O
period	O
followed	O
by	O
long	O
-	O
term	O
medical	B-DIS
management	I-DIS
of	O
sequelae	O
of	O
the	O
congenital	O
malformations	O
.	O

If	O
optimal	O
surgical	O
correction	O
is	O
achievable	O
the	O
prognosis	O
can	O
be	O
relatively	O
positive	O
though	O
some	O
patients	O
will	O
continue	O
to	O
be	O
affected	O
by	O
their	O
congenital	B-DIS
malformations	I-DIS
throughout	O
life	O
.	O

Importantly	O
patients	O
with	O
VACTERL	O
association	O
do	O
not	O
tend	O
to	O
have	O
neurocognitive	B-DIS
impairment	I-DIS
.	O

Ataxia	B-DIS
-	O
telangiectasia	O
is	O
the	O
second	O
most	O
common	O
autosomal	B-DIS
recessive	I-DIS
hereditary	O
ataxia	O
with	O
an	B-EPI
estimated	O
incidence	B-STAT
of	I-STAT
1	I-STAT
in	O
100000	O
births	O
.	O

Besides	O
ataxia	B-DIS
and	O
ocular	B-DIS
telangiectasias	I-DIS
eye	O
movement	B-DIS
abnormalities	I-DIS
have	O
long	O
been	O
associated	O
with	O
this	O
disorder	O
and	O
is	O
frequently	O
present	O
in	O
almost	O
all	O
patients	O
.	O

A	O
handful	O
of	O
studies	O
have	O
described	O
the	O
phenomenology	O
of	O
ocular	B-DIS
motor	I-DIS
deficits	I-DIS
in	O
ataxia	B-DIS
-	O
telangiectasia	O
.	O

Contemporary	O
literature	O
linked	O
their	O
physiology	O
to	O
cerebellar	B-DIS
dysfunction	I-DIS
and	O
secondary	B-DIS
abnormalities	I-DIS
at	I-DIS
the	I-DIS
level	O
of	O
brainstem	O
.	O

These	O
studies	O
while	O
providing	O
a	O
proof	O
of	O
concept	O
of	O
ocular	B-DIS
motor	I-DIS
physiology	O
in	O
disease	O
i.e	O
.	O

ataxia	B-DIS
-	O
telangiectasia	O
also	O
advanced	O
our	O
understanding	O
of	O
how	O
the	O
cerebellum	O
works	O
.	O

Here	O
we	O
will	O
summarize	O
the	O
clinical	O
abnormalities	O
seen	O
with	O
ataxia	B-DIS
-	O
telangiectasia	O
in	O
each	O
subtype	B-DIS
of	I-DIS
eye	O
movements	O
and	O
subsequently	O
describe	O
the	O
underlying	O
pathophysiology	O
.	O

Finally	O
we	O
will	O
review	O
how	O
these	O
deficits	O
are	O
linked	O
to	O
abnormal	O
cerebellar	O
function	O
and	O
how	O
it	O
allows	O
better	O
understanding	O
of	O
the	O
cerebellar	O
physiology	O
.	O

Background	O
In	O
this	O
nationwide	O
study	O
we	O
used	O
the	O
unique	O
Danish	O
registries	O
to	O
estimate	O
the	O
risk	O
of	O
suicide	O
and	O
deliberate	O
self	O
-	O
harm	O
in	O
patients	B-DIS
with	I-DIS
congenital	I-DIS
heart	O
disease	O
CHD	O
.	O

Methods	O
and	O
Results	O
We	O
identified	O
all	O
Danish	O
citizens	O
receiving	O
a	O
diagnosis	O
of	O
CHD	O
between	O
1977	O
and	O
2007	O
.	O

As	O
a	O
reference	O
cohort	O
we	O
randomly	O
selected	O
10	O
citizens	O
for	O
each	O
patient	O
matched	O
by	O
sex	O
and	O
birth	O
year	O
.	O

Using	O
the	O
Fine	O
and	O
Gray	O
competing	O
risk	O
regression	O
we	O
estimated	O
the	O
cumulative	O
incidences	B-EPI
of	O
suicide	O
and	O
self	B-DIS
-	O
harm	O
and	O
Cox	O
proportional	O
regression	O
analysis	O
was	O
used	O
to	O
compare	O
the	O
risk	O
of	O
suicide	O
and	O
deliberate	O
self	O
-	O
harm	O
in	O
patients	O
with	O
CHD	O
with	O
the	O
reference	O
cohort	O
.	O

We	O
identified	O
14433	O
patients	O
with	O
CHD	O
.	O

Mean	O
follow	O
-	O
up	O
was	O
21.3	O
years	O
with	O
a	O
maximum	O
follow	O
-	O
up	O
of	O
42	O
years	O
.	O

Since	O
the	O
time	O
of	O
diagnosis	O
2659	O
patients	O
had	O
died	O
with	O
a	O
median	O
age	O
of	O
death	B-DIS
of	O
23	O
years	O
.	O

A	O
total	O
of	O
15	O
patients	O
had	O
died	O
by	O
suicide	O
compared	O
with	O
232	O
suicides	O
in	O
the	O
reference	O
cohort	O
.	O

Patients	O
with	O
CHD	O
had	O
a	O
low	O
and	O
similar	O
risk	O
of	O
dying	O
by	O
suicide	O
when	O
compared	O
with	O
the	O
reference	O
cohort	O
cause	O
-	O
specific	O
hazard	O
ratio	O
0.81	O
;	O
95	B-STAT
%	I-STAT
CI	O
0.48	O
-	O
1.37	O
;	O
and	O
subhazard	O
ratio	O
0.68	O
;	O
95	B-STAT
%	I-STAT
CI	O
0.41	O
-	O
1.16	O
.	O

We	O
identified	O
336	O
events	O
of	O
self	B-DIS
-	O
harm	O
among	O
patients	O
with	O
CHD	O
and	O
3484	O
events	O
in	O
the	O
reference	O
group	O
.	O

The	O
overall	O
risk	O
of	O
deliberate	O
self	B-DIS
-	O
harm	O
was	O
not	O
increased	O
in	O
patients	O
with	O
CHD	O
when	O
compared	O
with	O
the	O
reference	O
group	O
subhazard	O
ratio	O
0.95	O
;	O
95	B-STAT
%	I-STAT
CI	O
0.85	O
-	O
1.06	O
.	O

Conclusions	O
This	O
is	O
the	O
first	O
study	O
to	O
estimate	O
the	O
risk	O
of	O
suicide	O
and	O
deliberate	O
self	O
-	O
harm	O
in	O
patients	O
with	O
CHD	O
.	O

We	O
found	O
that	O
patients	O
with	O
CHD	O
do	O
not	O
have	O
an	O
increased	O
risk	O
of	O
suicide	O
or	O
deliberate	O
self	B-DIS
-	O
harm	O
when	O
compared	O
with	O
a	O
large	O
reference	O
cohort	O
.	O

Congenital	B-DIS
adrenal	I-DIS
hyperplasia	I-DIS
is	O
the	O
most	O
common	O
cause	O
of	O
ambiguous	O
genitalia	O
worldwide	O
with	O
an	O
incidence	B-EPI
of	O
1	B-STAT
in	I-STAT
15000	I-STAT
live	O
births	O
.	O

The	O
most	O
frequently	O
-	O
occurring	B-DIS
subtype	I-DIS
21	O
-	O
hydroxylase	O
deficiency	O
results	O
in	O
diminished	O
production	O
of	O
aldosterone	O
and	O
cortisol	O
as	O
well	O
as	O
increased	O
androgen	O
secretion	O
.	O

Previous	O
studies	O
have	O
reported	O
a	O
relationship	O
between	O
ovarian	B-DIS
cyst	I-DIS
formation	O
and	O
adrenal	O
androgen	O
excess	O
;	O
nevertheless	O
neonatal	O
large	O
ovarian	B-DIS
cysts	I-DIS
have	O
rarely	O
been	O
reported	O
in	O
newborns	O
with	O
congenital	B-DIS
adrenal	I-DIS
hyperplasia	I-DIS
.	O

Herein	O
we	O
present	O
the	O
unique	O
case	O
of	O
a	O
neonate	O
with	O
classical	O
21	B-DIS
-	I-DIS
hydroxylase	O
deficiency	O
who	O
underwent	O
surgery	O
for	O
a	O
huge	O
unilateral	B-DIS
solitary	I-DIS
ovarian	I-DIS
follicular	O
cyst	O
on	O
the	O
seventh	O
postnatal	O
day	O
.	O

Possible	O
mechanisms	O
by	O
which	O
androgen	O
excess	O
may	O
cause	O
ovarian	B-DIS
cyst	I-DIS
formation	O
are	O
also	O
discussed	O
.	O

Central	O
hypothyroidism	B-DIS
CH	O
occurs	O
approximately	O
in	O
150000	O
and	O
therefore	O
is	O
expected	O
to	O
be	O
one	O
thousand	O
times	O
rarer	O
compared	O
with	O
primary	B-DIS
hypothyroidism	I-DIS
.	O

Despite	O
its	O
rarity	O
in	O
the	O
general	O
population	O
it	O
is	O
much	O
more	O
common	O
in	O
certain	O
disorders	O
in	O
which	O
it	O
is	O
frequently	O
associated	O
with	O
other	O
pituitary	B-DIS
hormone	I-DIS
deficiencies	I-DIS
.	O

The	O
aim	O
of	O
this	O
paper	O
is	O
to	O
provide	O
an	O
updated	O
review	O
on	O
the	O
frequency	O
of	O
congenital	B-DIS
CH	I-DIS
which	O
is	O
<	O
150000	O
and	O
on	O
its	O
etiology	O
disregarding	O
CH	O
caused	O
by	O
other	O
genetic	O
defects	O
such	O
as	O
mutations	O
of	O
transcription	O
factors	O
involved	O
in	O
pituitary	O
organogenesis	O
or	O
mutations	O
of	O
the	O
genes	O
encoding	O
TRH	O
or	O
TRH	O
receptor	O
.	O

Introduction	O
Niemann	B-DIS
-	I-DIS
Pick	I-DIS
type	O
C	O
NPC	O
is	O
a	O
lysosomal	O
storage	O
disease	O
that	O
is	O
progressive	O
and	O
life	O
-	O
limiting	B-EPI
with	O
an	O
estimated	O
incidence	O
of	O
1120000	O
live	O
births	O
.	O

In	O
addition	O
to	O
systemic	O
manifestation	O
with	O
hepato-	B-DIS
splenomegaly	I-DIS
there	O
are	O
a	O
number	O
of	O
neurological	B-DIS
manifestations	I-DIS
ataxia	B-DIS
dysarthria	I-DIS
dementia	I-DIS
cataplexy	I-DIS
epileptic	I-DIS
seizures	I-DIS
and	O
psychiatric	B-DIS
disorders	I-DIS
.	O

Characteristic	O
is	O
vertical	O
supranuclear	O
gaze	O
palsy	B-DIS
which	O
is	O
often	O
overlooked	O
.	O

Early	O
diagnosis	O
and	O
start	O
of	O
therapy	O
improve	O
quality	O
of	O
life	O
.	O

This	O
study	O
aimed	O
to	O
characterize	O
oculomotor	B-DIS
dysfunction	I-DIS
of	O
NPC	O
patients	O
and	O
to	O
provide	O
ophthalmologic	O
data	O
including	O
retinal	O
imaging	O
.	O

Methods	O
Eighteen	O
patients	O
with	O
biochemically	O
or	O
genetically	O
diagnosed	O
NPC	O
completed	O
oculomotor	O
and	O
ophthalmologic	O
examination	O
.	O

Ten	O
of	O
them	O
performed	O
saccadometry	O
by	O
infrared	O
based	O
video	O
-	O
oculography	O
.	O

Saccadic	O
parameters	O
were	O
compared	O
to	O
100	O
healthy	O
controls	O
and	O
were	O
correlated	O
with	O
clinical	O
variables	O
.	O

Another	O
subgroup	O
of	O
eight	O
patients	O
received	O
optical	O
coherence	O
tomography	O
OCT	O
of	O
the	O
optic	B-DIS
disc	I-DIS
and	O
the	O
macula	O
of	O
which	O
the	O
segmented	O
layers	O
were	O
analysed	O
using	O
a	O
crude	O
linear	O
mixed	O
model	O
and	O
one	O
adjusted	O
for	O
age	O
sex	O
and	O
spherical	O
equivalent	O
.	O

Results	O
Saccadometry	B-DIS
revealed	O
slowed	O
peak	O
velocity	O
compared	O
to	O
controls	O
most	O
evident	O
vertically	O
.	O

Peak	O
velocity	O
correlated	O
negatively	O
with	O
SARA	O
-	O
Score	O
but	O
correlation	O
with	O
clinical	O
assessment	O
of	O
saccades	O
was	O
not	O
significant	O
.	O

Clinical	O
features	O
in	O
the	O
assessment	O
of	O
vertical	O
saccades	O
were	O
intensive	O
blinking	O
and	O
head	B-DIS
movements	I-DIS
to	O
initiate	O
gaze	O
changes	O
and	O
lateral	O
trajectory	O
of	O
the	O
eyes	O
.	O

Macular	O
OCT	O
revealed	O
significant	O
total	O
retinal	B-DIS
thinning	I-DIS
in	O
the	O
fovea	O
specifically	O
of	O
the	O
outer	O
nuclear	O
layer	O
and	O
outer	O
retinal	O
layer	O
.	O

Para-	O
and	O
perifoveal	O
retinal	O
thicknesses	O
as	O
well	O
as	O
peripapillary	O
retinal	O
nerve	O
fibre	O
layer	O
were	O
normal	O
.	O

Conclusions	O
Foveal	O
thinning	O
was	O
revealed	O
in	O
NPC	O
.	O

It	O
remains	O
to	O
be	O
shown	O
whether	O
OCT	O
will	O
prove	O
to	O
be	O
useful	O
to	O
monitor	O
progression	O
.	O

Saccadic	B-DIS
impairment	I-DIS
reflects	O
CNS	O
involvement	O
and	O
therefore	O
is	O
a	O
parameter	O
to	O
demonstrate	O
the	O
progression	O
of	O
NPC	O
and	O
potentially	O
also	O
the	O
efficacy	O
of	O
new	O
therapies	O
.	O

Saccadometry	B-DIS
in	O
contrast	O
to	O
clinical	O
investigation	O
allows	O
the	O
precise	O
evaluation	O
of	O
saccades	O
.	O

Hemimelia	B-DIS
is	O
a	O
rare	O
anomaly	B-DIS
affecting	O
the	O
distal	O
long	O
bones	O
of	O
extremities	O
with	O
an	O
occurrence	O
of	O
1	B-STAT
-	I-STAT
20	I-STAT
cases	O
per	O
million	O
of	O
live	O
births	O
depending	O
on	O
the	O
affected	O
bone	O
.	O

Hemimelia	B-DIS
can	O
be	O
an	O
isolated	O
defect	O
or	O
be	O
part	O
of	O
complex	O
syndromes	O
that	O
affect	O
extra	O
skeletal	O
structures	O
.	O

Prenatal	O
detection	O
by	O
routine	O
ultrasound	O
imaging	O
is	O
difficult	O
and	O
yields	O
low	O
detection	O
rates	O
.	O

The	O
prenatal	O
diagnosis	O
of	O
hemimelia	B-DIS
should	O
prompt	O
a	O
complete	O
and	O
detailed	O
study	O
of	O
the	O
fetal	O
anatomy	O
since	O
it	O
can	O
be	O
associated	O
with	O
defects	O
in	O
other	O
structures	O
and	O
systems	O
as	O
the	O
reported	O
in	O
this	O
case	O
.	O

The	O
prognosis	O
depends	O
upon	O
the	O
associated	O
anomalies	B-DIS
.	O

Larsen	B-DIS
syndrome	I-DIS
OMIM	I-DIS
150250	I-DIS
was	O
first	O
described	O
in	O
1950	O
as	O
an	O
entity	O
characterized	O
by	O
distinct	O
facial	O
features	O
and	O
dislocations	O
of	O
the	O
multiple	O
large	O
joint	O
and	O
cleft	B-DIS
palate	I-DIS
hearing	I-DIS
loss	I-DIS
and	O
spinal	B-DIS
abnormalities	I-DIS
were	O
occasionally	O
observed	O
.	O

The	O
prevalence	B-EPI
of	O
Larsen	B-DIS
syndrome	I-DIS
is	O
estimated	O
to	O
be	O
one	B-STAT
in	I-STAT
100000	I-STAT
live	O
births	O
.	O

Management	O
of	O
multiple	O
large	B-DIS
-	I-DIS
joint	O
dislocations	O
often	O
proves	O
difficult	O
with	O
a	O
tendency	O
toward	O
recurrence	O
particularly	O
if	O
a	O
patient	O
has	B-DIS
complete	I-DIS
dislocation	I-DIS
of	I-DIS
the	O
knee	O
.We	O
treated	O
a	O
boy	O
with	O
the	O
clinical	O
phenotype	B-DIS
of	I-DIS
Larsen	O
syndrome	O
using	O
10	O
orthopedic	O
procedures	O
but	O
failed	O
to	O
achieve	O
a	O
satisfactory	O
outcome	O
.	O
The	O
aim	O
of	O
this	O
report	O
is	O
to	O
review	O
the	O
surgical	O
course	O
and	O
report	O
results	O
of	O
surgical	O
treatments	O
for	O
this	O
patient	O
with	O
12	O
years	O
of	O
follow	O
-	O
up	O
.	O

Since	O
the	O
discovery	O
of	O
the	O
FMR1	O
gene	O
and	O
the	O
clinical	O
and	O
molecular	O
characterization	O
of	O
Fragile	B-DIS
X	I-DIS
Syndrome	I-DIS
in	O
1991	O
more	O
than	O
141	O
genes	O
have	O
been	O
identified	O
in	O
the	O
X	O
-	O
chromosome	O
in	O
these	O
28	O
years	O
thanks	O
to	O
applying	O
continuously	O
evolving	O
molecular	O
techniques	B-DIS
to	I-DIS
X	I-DIS
-	I-DIS
linked	O
intellectual	O
disability	O
XLID	O
families	O
.	O

In	O
the	O
past	O
decade	O
array	O
comparative	O
genomic	O
hybridization	O
and	O
next	O
generation	O
sequencing	O
technologies	O
have	O
accelerated	O
gene	O
discovery	O
exponentially	O
.	O

Classically	O
XLID	B-DIS
has	O
been	O
subdivided	O
in	O
syndromic	B-DIS
intellectual	I-DIS
disability	I-DIS
S	O
-	O
XLID	B-DIS
-where	I-DIS
intellectual	O
disability	O
ID	O
is	O
always	O
associated	O
with	O
other	O
recognizable	O
physical	O
and/or	O
neurological	O
features	O
-	B-DIS
and	I-DIS
non	I-DIS
-	O
specific	O
or	O
non	O
-	O
syndromic	O
intellectual	O
disability	O
NS	O
-	O
XLID	O
where	O
the	O
only	O
common	O
feature	O
is	O
ID	O
.	O

Nevertheless	O
new	O
advances	O
on	O
the	O
study	O
of	O
these	O
entities	O
have	O
showed	O
that	O
this	O
classification	O
is	O
not	O
always	O
clear	O
-	O
cut	O
because	O
distinct	O
variants	O
in	O
several	O
of	B-DIS
these	O
XLID	O
genes	O
can	O
result	O
in	O
S	O
-	O
XLID	O
as	O
well	O
as	O
in	O
NS	O
-	O
XLID	O
.	O

This	O
review	O
focuses	O
on	O
the	O
current	O
knowledge	O
on	O
the	O
XLID	B-DIS
genes	O
involved	O
in	O
non	B-DIS
-	O
syndromic	O
forms	O
with	O
the	O
emphasis	O
on	O
their	O
pathogenic	O
mechanism	O
thus	O
allowing	O
the	O
possibility	O
to	O
elucidate	O
why	O
some	O
of	O
them	O
can	O
give	O
both	O
syndromic	B-DIS
and	O
non	O
-	O
syndromic	O
phenotypes	O
.	O

Objective	O
Intellectual	O
Disability	O
ID	O
represents	O
a	O
neuropsychiatric	B-DIS
disorder	I-DIS
which	O
its	O
etiopathogenesis	O
remains	O
insufficiently	O
understood	O
.	O

Mutations	O
in	O
the	O
Aristaless	O
Related	O
Homeobox	O
gene	O
ARX	B-DIS
have	O
been	O
identified	O
to	O
cause	O
syndromic	O
and	O
nonsyndromic	B-DIS
NS	I-DIS
-	O
ID	O
.	O

The	O
most	O
recurrent	O
mutation	O
of	O
this	O
gene	O
is	O
a	O
duplication	O
of	O
24pb	O
c.428	O
-	O
451dup	O
.	O

Epidemiological	O
and	O
genetic	O
studies	O
about	O
ID	O
in	O
the	O
Moroccan	O
population	O
remain	O
very	O
scarce	O
and	O
none	O
study	O
is	O
carried	O
out	O
on	O
the	O
ARX	B-DIS
gene	O
.	O

This	O
work	O
aimed	O
to	O
study	O
c.428	O
-	O
451dup	O
24	O
bp	O
mutation	O
in	O
the	O
exon	O
2	O
of	O
the	O
ARX	B-DIS
gene	O
in	O
118	O
males	O
'	O
Moroccan	O
patients	O
with	O
milder	O
NS	O
-	O
ID	O
to	O
evaluate	O
if	O
the	O
gene	O
screening	O
is	O
a	O
good	O
tool	O
for	O
identifying	O
NS	O
-	O
ID	O
.	O

Results	O
Our	O
mutational	O
analysis	O
did	O
not	O
show	O
any	O
dup	O
24pb	O
in	O
our	O
patients	O
.	O

This	O
is	O
because	O
based	O
on	O
findings	O
from	O
previous	O
studies	O
that	O
found	O
ARX	B-DIS
mutations	O
in	O
70	B-STAT
%	I-STAT
of	O
families	O
with	O
NS	O
-	O
ID	O
and	O
in	O
most	O
cases	O
1.5	B-STAT
-	I-STAT
6.1	I-STAT
%	I-STAT
of	O
individuals	O
with	O
NS	O
-	O
ID	O
have	O
this	O
duplication	O
.	O

Since	O
1/118	B-STAT
=	O
0.0084	B-STAT
0.84	I-STAT
%	I-STAT
is	O
not	O
much	O
different	O
from	O
1.5	B-STAT
%	I-STAT
then	O
it	O
is	O
reasonable	O
that	O
this	O
could	O
a	O
sample	O
size	O
artifact	O
.	O

A	O
complete	O
screening	O
of	O
the	O
entire	O
ARX	O
gene	O
including	O
the	O
five	O
exons	O
should	O
be	O
fulfilled	O
.	O

Further	O
investigations	O
are	O
required	O
to	O
confirm	O
these	O
results	O
.	O

Charcot	B-DIS
-	I-DIS
Marie	O
-	O
Tooth	O
CMT	O
is	O
the	O
most	O
prevalent	B-DIS
category	O
of	O
inherited	O
neuropathy	O
.	O

The	O
most	O
common	O
inheritance	O
pattern	O
is	O
autosomal	O
dominant	O
though	O
there	O
also	O
are	O
X	O
-	O
linked	O
and	O
autosomal	O
recessive	O
subtypes	O
.	O

In	O
addition	O
to	O
a	O
variety	O
of	O
inheritance	O
patterns	O
there	O
are	O
a	O
myriad	O
of	O
genes	O
associated	O
with	O
CMT	B-DIS
reflecting	O
the	O
heterogeneity	O
of	O
this	O
disorder	O
.	O

Next	O
generation	O
sequencing	O
NGS	O
has	O
expanded	O
and	O
simplified	O
the	O
diagnostic	O
yield	O
of	O
genes	O
/	O
molecules	O
underlying	O
and/or	O
associated	B-DIS
with	O
CMT	O
which	O
is	O
of	O
paramount	O
importance	O
in	O
providing	O
a	O
substrate	O
for	O
current	O
and	O
future	O
targeted	O
disease	O
-	O
modifying	O
treatment	O
options	O
.	O

Considerable	O
research	O
attention	O
for	O
disease	O
-	O
modifying	O
therapy	O
has	O
been	O
geared	O
towards	O
the	O
most	O
commonly	O
encountered	O
genetic	O
mutations	O
PMP22	O
GJB1	O
MPZ	O
and	O
MFN2	O
.	O

In	O
this	O
review	O
we	O
highlight	O
the	O
clinical	O
background	O
molecular	O
understanding	O
and	O
therapeutic	O
investigations	O
of	O
these	O
CMT	B-DIS
subtypes	O
while	O
also	O
discussing	O
therapeutic	O
research	O
pertinent	O
to	O
the	O
remaining	O
less	O
common	O
CMT	B-DIS
subtypes	O
.	O

Congenital	B-DIS
adrenal	I-DIS
hyperplasia	I-DIS
CAH	I-DIS
was	O
the	O
fourth	O
disorder	O
added	O
to	O
the	O
national	O
Swedish	O
neonatal	O
screening	O
program	O
in	O
1986	O
and	O
approximately	O
115000	O
newborns	O
are	O
screened	O
annually	O
.	O

Dried	O
blood	O
spot	O
DBS	O
screening	O
with	O
measurement	O
of	O
17	O
-	O
hydroxyprogesterone	O
17OHP	O
is	O
also	O
offered	O
to	O
older	O
children	O
moving	O
to	O
Sweden	B-LOC
from	O
countries	O
lacking	O
a	O
national	O
DBS	O
screening	O
program	O
.	O

Here	O
we	O
report	O
an	O
update	O
on	O
the	O
CAH	O
screening	O
from	O
January	O
2011	O
until	O
December	O
2019	O
.	O

Results	O
During	O
the	O
study	O
period	O
1030409	O
newborns	O
and	O
34713	O
older	O
children	O
were	O
screened	O
.	O

In	O
total	O
87	O
newborns	O
were	O
verified	O
to	O
have	O
CAH	B-DIS
which	O
gives	O
an	O
overall	O
positive	O
predictive	O
value	O
PPV	O
of	O
11	B-STAT
%	I-STAT
and	O
21	B-STAT
%	I-STAT
for	O
term	O
infants	O
.	O

Including	O
the	O
five	O
missed	O
CAH	B-DIS
cases	O
identified	O
during	O
this	O
period	O
this	O
gives	O
an	O
incidence	B-EPI
of	O
111200	O
of	O
CAH	B-DIS
in	O
Sweden	B-LOC
.	O

Among	O
the	O
older	O
children	O
12	O
of	O
14	O
recalled	O
cases	O
were	O
found	O
to	O
be	O
true	O
positive	O
for	O
CAH	B-DIS
.	O

All	O
patients	O
were	O
genotyped	O
as	O
part	O
of	O
the	O
clinical	O
follow	O
-	O
up	O
and	O
70	B-STAT
%	I-STAT
of	O
the	O
newborns	B-DIS
had	I-DIS
salt	O
wasting	B-DIS
SW	O
CAH	O
and	O
92	B-STAT
%	I-STAT
had	B-DIS
classic	O
CAH	O
i.e	O
.	O

SW	O
and	O
simple	O
virilizing	O
SV	O
CAH	B-DIS
.	O

In	O
the	O
group	O
of	O
12	O
older	O
children	O
none	O
had	O
SW	O
CAH	B-DIS
and	O
two	O
had	O
SV	O
CAH	B-DIS
.	O

Conclusion	O
The	O
incidence	B-EPI
of	O
classic	O
CAH	B-DIS
is	O
relatively	O
high	O
in	O
Sweden	B-LOC
.	O

Early	O
genetic	O
confirmation	O
with	O
CYP21A2	O
genotyping	O
has	O
been	O
a	O
valuable	O
complement	O
to	O
the	O
analysis	O
of	O
17OHP	O
to	O
predict	O
disease	O
severity	O
make	O
treatment	O
decisions	O
and	O
for	O
the	O
follow	O
-	O
up	O
and	O
evaluation	O
of	O
the	O
screening	O
program	O
.	O

OBJECTIVESTo	O
describe	O
the	O
prevalence	B-EPI
of	O
the	O
reduced	O
ankle	O
-	O
brachial	O
index	O
ABI	O
in	O
patients	B-DIS
with	I-DIS
heart	O
failure	O
HF	O
with	O
preserved	O
ejection	O
fraction	O
HFpEF	O
attended	O
at	O
a	O
HF	O
clinic	O
in	O
the	O
metropolitan	O
region	O
of	O
Porto	B-LOC
Alegre	I-LOC
and	O
to	O
compar	O
the	O
patients	O
to	O
those	O
with	O
reduced	O
ejection	O
fraction	O
HFrEF	O
.	O

METHODSA	O
descriptive	O
observational	O
study	O
included	O
patients	O
referred	O
to	O
the	O
heart	B-DIS
failure	I-DIS
clinic	O
in	O
HU	O
-	O
Ulbra	O
with	O
HFpEF	O
or	O
HFrEF	O
and	O
diastolic	O
dysfunction	O
and	O
measurements	O
of	O
ABIs	O
using	O
vascular	O
Doppler	O
equipment	O
were	O
performed	O
in	O
both	O
groups	O
.	O

RESULTSThe	O
sample	O
consisted	O
of	O
106	O
patients	O
with	O
HF	O
53.9	B-STAT
%	I-STAT
of	O
the	O
patients	O
had	O
HFpEF	B-DIS
and	O
19.4	B-STAT
%	I-STAT
had	O
a	O
diagnosis	O
of	O
peripheral	B-DIS
arterial	I-DIS
disease	I-DIS
PAD	O
ABI	O
less	O
than	O
0.9	O
.	O

PAD	O
was	O
identified	O
in	O
24.1	B-STAT
%	I-STAT
of	O
the	O
patients	O
with	O
HFpEF	O
while15.8	O
%	O
of	O
patients	O
in	O
the	O
HFrEF	O
group	O
were	O
diagnosed	O
with	O
PAD	B-DIS
.	O

CONCLUSIONOur	O
results	O
did	O
not	O
identify	O
a	O
significantly	O
different	O
prevalence	B-EPI
of	O
altered	O
and	O
compatible	O
PAD	O
values	O
in	O
patients	O
with	O
HFpEF	B-DIS
.	O

However	O
we	O
showed	O
a	O
prevalence	B-EPI
of	O
19.4	B-STAT
%	I-STAT
a	O
high	O
value	O
if	O
we	O
consider	O
similar	O
populations	O
.	O

Over	O
90	O
years	O
ago	O
Otto	B-DIS
Warburg	O
's	O
seminal	O
discovery	O
of	O
aerobic	O
glycolysis	O
established	O
metabolic	O
reprogramming	O
as	O
one	O
of	O
the	O
first	O
distinguishing	O
characteristics	O
of	O
cancer	O
1	O
<	O
/s	O
.	O

The	O
field	O
of	O
cancer	B-DIS
metabolism	O
subsequently	O
revealed	O
additional	O
metabolic	B-DIS
alterations	I-DIS
in	O
cancer	B-DIS
by	O
focusing	O
on	O
central	O
carbon	O
metabolism	O
including	O
the	O
citric	O
acid	O
cycle	O
and	O
pentose	O
phosphate	O
pathway	O
.	O

Recent	O
reports	O
have	O
however	O
uncovered	O
substantial	O
non	O
-	O
carbon	O
metabolism	O
contributions	B-DIS
to	O
cancer	O
cell	O
viability	O
and	O
growth	O
.	O

Amino	O
acids	O
nutrients	O
vital	O
to	O
the	O
survival	O
of	O
all	O
cell	O
types	O
experience	O
reprogrammed	O
metabolism	O
in	O
cancer	B-DIS
.	O

This	O
review	O
outlines	O
the	O
diverse	O
roles	O
of	O
amino	O
acids	O
within	O
the	O
tumor	B-DIS
and	O
in	O
the	O
tumor	B-DIS
microenvironment	O
.	O

Beyond	O
their	O
role	O
in	O
biosynthesis	O
they	O
serve	O
as	O
energy	O
sources	O
and	O
help	O
maintain	O
redox	O
balance	O
.	O

In	O
addition	O
amino	O
acid	O
derivatives	O
contribute	O
to	O
epigenetic	O
regulation	O
and	O
immune	O
responses	O
linked	O
to	O
tumorigenesis	O
and	O
metastasis	B-DIS
.	O

Furthermore	O
in	O
discussing	O
the	O
transporters	O
and	O
transaminases	O
that	O
mediate	O
amino	O
acid	O
uptake	O
and	O
synthesis	O
we	O
identify	O
potential	O
metabolic	O
liabilities	O
as	O
targets	O
for	O
therapeutic	O
intervention	O
.	O

MYO15A	O
is	O
the	O
third	O
most	O
crucial	O
gene	O
in	O
hereditary	B-DIS
sensorineural	I-DIS
hearing	I-DIS
loss	I-DIS
after	O
GJB2	O
and	O
SLC26A4	B-DIS
.	O

In	O
the	O
present	O
study	O
we	O
reviewed	O
the	O
prevalence	B-EPI
of	O
MYO15A	O
mutations	O
in	O
patients	O
with	O
autosomal	B-DIS
recessive	I-DIS
non	I-DIS
-	I-DIS
syndromic	I-DIS
hearing	I-DIS
loss	O
ARNSHL	O
.	O

In	O
this	O
meta	O
-	O
analysis	O
we	O
conducted	O
a	O
search	O
of	O
PubMed	O
Web	O
of	O
Science	O
Excerpta	O
Medica	O
Database	O
and	O
Scopus	O
and	O
identified	O
the	O
articles	O
up	O
to	O
September	O
2019	O
without	O
any	O
time	O
limit	O
.	O

Two	O
investigators	O
independently	O
selected	O
the	O
relevant	O
papers	O
and	O
extracted	O
the	O
required	O
information	O
.	O

A	O
total	O
of	O
44	O
case	O
-	O
control	O
and	O
case	O
series	O
studies	O
were	O
considered	O
and	O
4176	O
patients	O
and	O
3706	O
healthy	O
individuals	O
as	O
the	O
control	O
group	O
were	O
included	O
.	O

The	O
pooled	O
frequency	O
of	O
MYO15A	O
mutations	O
between	O
patients	O
suffering	O
from	O
ARNSHL	B-DIS
was	O
calculated	O
as	O
6.2	B-STAT
%	I-STAT
95	B-STAT
%	I-STAT
CI	O
4.9	O
-	O
7.8	O
P	O
-value	O
<	O
0.001	O
.	O

There	O
was	O
heterogeneity	O
between	O
our	O
studies	O
P	O
-value	O
<	O
0.001	O
I2=58.1	O
%	O
;	O
therefore	O
the	O
random	O
-	O
effects	O
model	O
was	O
utilized	O
for	O
analysis	O
.	O

Given	O
the	O
results	O
in	O
many	O
countries	O
the	O
MYO15A	O
gene	O
has	O
a	O
significant	O
contribution	O
to	O
hearing	B-DIS
loss	I-DIS
.	O

Moreover	O
in	O
several	O
regions	O
specific	O
dominant	O
mutations	O
in	O
this	O
gene	O
have	O
been	O
reported	O
.	O

Therefore	O
the	O
ethnic	O
background	O
should	O
be	O
considered	O
to	O
investigate	O
the	O
mutations	O
of	O
the	O
MYO15A	O
gene	O
.	O

Premature	B-DIS
loss	I-DIS
of	I-DIS
ovarian	I-DIS
activity	O
before	O
40	O
years	O
of	O
age	O
is	O
known	O
as	O
primary	B-DIS
ovarian	I-DIS
insufficiency	I-DIS
POI	I-DIS
and	O
occurs	O
in	O
∼1	O
%	O
of	O
women	O
.	O

A	O
more	O
subtle	O
decline	O
in	O
ovarian	O
activity	O
known	O
as	O
premature	B-DIS
ovarian	I-DIS
ageing	O
POA	O
occurs	O
in	O
∼10	O
%	O
of	O
women	O
.	O

Despite	O
the	O
high	O
prevalence	B-EPI
of	O
POA	O
very	O
little	O
is	O
known	O
regarding	O
its	O
genetic	O
causation	O
.	O

Senataxin	O
SETX	B-DIS
is	O
an	O
RNA	O
/	O
DNA	O
helicase	O
involved	O
in	O
repair	O
of	O
oxidative	O
stress	O
-	O
induced	O
DNA	O
damage	O
.	O

Homozygous	O
mutation	O
of	O
SETX	B-DIS
leads	O
to	O
the	O
neurodegenerative	B-DIS
disorder	I-DIS
ataxia	I-DIS
oculomotor	I-DIS
apraxia	I-DIS
type	I-DIS
2	I-DIS
AOA2	I-DIS
.	O

There	O
have	O
been	O
reports	O
of	O
POI	B-DIS
in	O
AOA2	B-DIS
females	O
suggesting	O
a	O
link	O
between	O
SETX	B-DIS
and	O
ovarian	O
ageing	O
.	O

Here	O
we	O
studied	O
female	O
mice	O
lacking	O
either	O
one	O
Setx+/-	O
or	O
both	O
Setx-/-	O
copies	O
of	O
SETX	B-DIS
over	O
a	O
12-	O
to	O
14	O
-	O
month	O
period	O
.	O

We	O
find	O
that	O
DNA	O
damage	O
is	O
increased	O
in	O
oocytes	O
from	O
8	O
-	O
month	O
-	O
old	O
Setx+/-	O
and	O
Setx-/-	O
females	O
compared	O
with	O
Setx+/+	O
oocytes	O
leading	O
to	O
a	O
marked	O
reduction	O
in	O
all	O
classes	O
of	O
ovarian	O
follicles	O
at	O
least	O
4	O
months	O
earlier	O
than	O
typically	O
occurs	O
in	O
female	O
mice	O
.	O

Furthermore	O
during	O
a	O
12	O
-	O
month	O
long	O
mating	O
trial	O
Setx+/-	O
and	O
Setx-/-	O
females	O
produced	O
significantly	O
fewer	O
pups	O
than	O
Setx+/+	O
females	O
from	O
7	O
months	O
of	O
age	O
onwards	O
.	O

These	O
data	O
show	O
that	O
SETX	B-DIS
is	O
critical	O
for	O
preventing	O
POA	O
in	O
mice	O
likely	O
by	O
preserving	O
DNA	O
integrity	O
in	O
oocytes	O
.	O

Intriguingly	O
heterozygous	O
Setx	O
loss	O
causes	O
an	O
equally	O
severe	O
impact	O
on	O
ovarian	O
ageing	O
as	O
homozygous	O
Setx	O
loss	O
.	O

Because	O
heterozygous	O
SETX	B-DIS
disruption	O
is	O
less	O
likely	O
to	O
produce	O
systemic	O
effects	O
SETX	B-DIS
compromise	O
could	O
underpin	O
some	O
cases	O
of	O
insidious	O
POA	O
.	O

Methods	O
We	O
analyzed	O
high	O
-	O
resolution	O
CT	O
HRCT	O
findings	O
from	O
six	O
male	O
patients	O
mean	O
age	O
22.6	O
years	O
with	O
confirmed	O
diagnoses	B-DIS
of	I-DIS
acute	I-DIS
Q	O
fever	O
.	O

Two	O
chest	O
radiologists	O
analyzed	O
the	O
images	O
and	O
reached	O
decisions	O
by	O
consensus	O
.	O

All	O
patients	O
presented	O
fever	B-DIS
myalgia	I-DIS
prostation	I-DIS
headache	I-DIS
and	O
dry	B-DIS
cough	I-DIS
.	O

They	O
also	O
had	O
common	O
epidemiologic	O
factors	O
recent	O
travel	O
for	O
military	O
service	O
where	O
they	O
had	O
contact	O
with	O
sheep	O
and	O
capybara	O
.	O

Diagnoses	O
were	O
confirmed	O
by	O
the	O
detection	O
of	O
C.	O
burnetii	O
DNA	O
in	O
clinical	O
samples	O
by	O
polymerase	O
chain	O
reaction	O
.	O

Results	O
The	O
predominant	O
HRCT	O
findings	O
were	O
areas	O
of	O
consolidation	O
100	B-STAT
%	I-STAT
and	O
nodules	O
66.6	B-STAT
%	I-STAT
with	O
halos	O
of	O
ground	B-DIS
-	I-DIS
glass	O
opacity	O
predominantly	O
with	O
segmental	O
and	O
peripheral	O
distributions	O
.	O

Lesions	O
affected	O
all	O
lobes	O
and	O
predominated	O
in	O
the	O
left	O
upper	O
and	O
lower	O
lobes	O
.	O

Involvement	O
of	O
more	O
than	O
one	O
lobe	O
was	O
observed	O
in	O
four	O
patients	O
.	O

No	O
pleural	B-DIS
effusion	I-DIS
or	O
lymph	O
node	O
enlargement	O
was	O
found	O
.	O

Conclusion	O
The	O
predominant	O
HRCT	O
findings	O
in	O
patients	O
with	O
acute	B-DIS
Q	I-DIS
fever	I-DIS
pneumonia	I-DIS
were	O
bilateral	O
peripheral	O
areas	O
of	O
consolidation	O
and	O
nodules	O
with	O
irregular	O
contours	O
and	O
halos	O
of	O
ground	B-DIS
-	I-DIS
glass	O
opacity	O
.	O

Advances	O
in	O
knowledge	O
Acute	B-DIS
Q	I-DIS
fever	I-DIS
should	O
be	O
included	O
in	O
the	O
differential	O
diagnosis	O
of	O
lesions	O
with	O
the	O
halo	O
sign	O
on	O
HRCT	O
.	O

Background	O
Pathogenic	O
intestinal	O
protozoa	O
are	O
considered	O
as	O
a	O
serious	O
public	O
health	O
problem	O
in	O
developing	O
countries	O
.	O

This	O
study	O
aimed	O
to	O
elucidate	O
the	O
overall	O
prevalence	B-EPI
and	O
spatial	O
distribution	O
of	O
three	O
common	O
human	O
pathogenic	O
intestinal	B-DIS
protozoan	I-DIS
infections	I-DIS
in	O
Iran	B-LOC
.	O

Methods	O
Six	O
English	O
and	O
Persian	O
databases	O
were	O
explored	O
for	O
published	O
papers	O
on	O
the	O
prevalence	B-EPI
of	O
Entamoeba	B-DIS
histolytica	I-DIS
/	I-DIS
dispar	I-DIS
Giardia	O
lamblia	O
and	O
Cryptosporidium	O
spp	O
.	O

in	O
the	O
general	O
population	O
of	O
Iran	B-LOC
from	O
2000	O
to	O
2015	O
.	O

All	O
eligible	O
data	O
were	O
collected	O
using	O
a	O
pre	O
-	O
designed	O
data	O
extraction	O
form	O
and	O
the	B-EPI
overall	O
prevalence	O
was	O
estimated	O
using	O
a	O
random	O
-	O
effects	O
meta	O
-	O
analysis	O
model	O
.	O

We	O
used	O
ArcMap	O
for	O
mapping	O
the	O
prevalence	B-EPI
of	O
the	O
studied	O
protozoa	O
and	O
clustering	O
analysis	O
.	O

Results	O
Altogether	O
118	O
eligible	O
papers	O
from	O
24	O
provinces	O
of	O
Iran	B-LOC
were	O
included	O
and	O
analyzed	O
.	O

The	O
weighted	O
prevalence	B-EPI
of	O
E.	B-DIS
histolytica	I-DIS
/	I-DIS
dispar	I-DIS
G.	O
lamblia	O
and	O
Cryptosporidium	O
spp	O
.	O

infection	B-DIS
among	O
Iranian	O
general	O
population	O
were	O
calculated	O
1.3	B-STAT
%	I-STAT
95	B-STAT
%	I-STAT
CI	O
1.1	B-STAT
-	I-STAT
1.5	I-STAT
%	I-STAT
10.6	B-STAT
%	I-STAT
95	B-STAT
%	I-STAT
CI	O
9.6	B-STAT
-	I-STAT
11.5	I-STAT
%	I-STAT
and	I-STAT
2	B-STAT
%	I-STAT
95	B-STAT
%	I-STAT
CI	O
1.5	B-STAT
-	I-STAT
2.5	I-STAT
%	I-STAT
respectively	O
.	O

Conclusion	O
Our	O
findings	O
indicated	O
human	O
intestinal	B-DIS
protozoan	I-DIS
infections	I-DIS
caused	O
by	O
E.	O
histolytica	O
/	O
dispar	O
G.	O
lamblia	O
and	O
Cryptosporidium	O
spp	O
.	O

have	O
still	O
public	O
health	O
importance	O
in	O
some	O
parts	O
of	O
Iran	B-LOC
.	O

Objectives	O
Neonatal	O
herpes	B-DIS
simplex	I-DIS
virus	O
HSV	B-DIS
infections	I-DIS
are	O
associated	O
with	O
high	O
mortality	O
and	O
long	O
-	O
term	O
morbidity	O
.	O

However	O
incidence	B-EPI
is	O
low	O
and	O
acyclovir	O
the	O
treatment	O
of	O
choice	O
carries	O
risk	O
of	O
toxicity	B-DIS
.	O

We	O
aimed	O
to	O
increase	O
the	O
percentage	O
of	O
patients	O
0	O
to	O
60	O
days	O
of	O
age	O
who	O
are	O
tested	O
and	O
treated	O
for	O
HSV	O
in	O
accordance	O
with	O
local	O
guideline	O
recommendations	O
from	O
40	B-STAT
%	I-STAT
to	I-STAT
80	I-STAT
%	I-STAT
.	O

Methods	O
This	O
quality	O
improvement	O
project	O
took	O
place	O
at	O
1	O
freestanding	O
children	O
's	O
hospital	O
.	O

Multiple	O
plan	O
-	O
do	O
-	O
study	O
-	O
act	O
cycles	O
were	O
focused	O
on	O
interventions	O
aimed	O
at	O
key	O
drivers	O
including	O
provider	O
buy	O
-	O
in	O
guideline	O
availability	O
and	O
accurate	O
identification	O
of	O
high	O
-	O
risk	O
patients	O
.	O

A	O
run	O
chart	O
was	O
used	O
to	O
track	O
the	O
effect	O
of	O
interventions	O
on	O
the	O
percentage	O
managed	O
per	O
guideline	O
recommendations	O
over	O
time	O
by	O
using	O
established	O
rules	O
for	O
determining	O
special	O
cause	O
.	O

Pre-	O
and	O
postimplementation	O
acyclovir	O
use	O
was	O
compared	O
by	O
using	O
a	O
χ	O
2	O
<	O
/s	O
test	O
.	O

In	O
HSV	O
-	O
positive	O
cases	O
delayed	O
acyclovir	O
initiation	O
defined	O
a	O
1	O
day	O
from	O
presentation	O
was	O
tracked	O
as	O
a	O
balancing	O
measure	O
.	O

Results	O
The	O
median	O
percentage	O
of	O
patients	O
managed	O
according	O
to	O
guideline	O
recommendations	O
increased	O
from	O
40	B-STAT
%	I-STAT
to	I-STAT
80	I-STAT
%	I-STAT
within	O
8	O
months	O
.	O

Acyclovir	O
use	O
decreased	O
from	O
26	B-STAT
%	I-STAT
to	O
7.9	B-STAT
%	I-STAT
P	O
<	O
.001	O
in	O
non	O
-	O
high	O
-	O
risk	O
patients	O
but	O
did	O
not	O
change	O
significantly	O
in	O
high	O
-	O
risk	O
patients	O
73	B-STAT
%	I-STAT
-83	B-STAT
%	I-STAT
;	O
P	O
=	O
.15	O
.	O

There	O
were	O
no	O
cases	O
of	O
delayed	O
acyclovir	O
initiation	O
in	O
HSV	O
-	O
positive	O
cases	O
.	O

Conclusions	O
Point	O
-	O
of	O
-	O
care	O
availability	O
of	O
an	O
evidence	O
-	O
based	O
guideline	O
and	O
interventions	O
targeted	O
at	O
provider	O
engagement	O
improved	O
adherence	O
to	O
a	O
new	O
guideline	O
for	O
neonatal	O
HSV	O
management	O
and	O
decreased	O
acyclovir	O
use	O
in	O
non	O
-	O
high	O
-	O
risk	O
infants	O
.	O

Further	O
study	O
is	O
necessary	O
to	O
confirm	O
the	O
safety	O
of	O
these	O
recommendations	O
in	O
other	O
settings	O
.	O

